Document:

EX-10.5

 Exhibit 10.5 

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND
(II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 
 SPONSORED RESEARCH COLLABORATION AGREEMENT 

BY AND BETWEEN 
 THE
INSTITUTE OF MOLECULAR AND CLINICAL OPHTHALMOLOGY BASEL 
 AND 

AFFINIA THERAPEUTICS INC. 

 TABLE OF CONTENTS 

 

									
	 	 	 	  	 	  	Page	 
			
	1.	 	 DEFINITIONS AND INTERPRETATION
	  	 	1	 
				
		 	1.1	  	 Definitions
	  	 	1	 
				
		 	1.2	  	 Interpretation
	  	 	6	 
			
	2.	 	 RESEARCH COLLABORATION
	  	 	6	 
				
		 	2.1	  	 Scope
	  	 	6	 
				
		 	2.2	  	 Research Term
	  	 	6	 
				
		 	2.3	  	 Research Plan
	  	 	6	 
				
	    	 	2.4	  	 Research Budget
	  	 	7	 
				
		 	2.5	  	 Conduct of Research Activities
	  	 	7	 
				
		 	2.6	  	 Principal Investigator
	  	 	7	 
				
		 	2.7	  	 Subcontractors
	  	 	7	 
				
		 	2.8	  	 Research Records
	  	 	7	 
				
		 	2.9	  	 Research Reports
	  	 	7	 
				
		 	2.10	  	 Materials
	  	 	7	 
				
		 	2.11	  	 Research Costs and Payment
	  	 	8	 
			
	3.	 	 GOVERNANCE
	  	 	8	 
				
		 	3.1	  	 Joint Research Committee
	  	 	8	 
				
		 	3.2	  	 Representatives and Meetings
	  	 	8	 
				
		 	3.3	  	 Resolution of Disputes
	  	 	9	 
			
	4.	 	 INTELLECTUAL PROPERTY RIGHTS
	  	 	9	 
				
		 	4.1	  	 Background IP
	  	 	9	 
				
		 	4.2	  	 Collaboration Patents
	  	 	10	 
				
		 	4.3	  	 Patent Prosecution and Maintenance of Collaboration Patents
	  	 	11	 
				
		 	4.4	  	 Enforcement of Joint Patents
	  	 	11	 
				
		 	4.5	  	 Use of [***] on Joint Patents
	  	 	11	 
				
		 	4.6	  	 Option Rights of Affinia
	  	 	12	 
				
		 	4.7	  	 Research and Development Licenses
	  	 	12	 
				
		 	4.8	  	 No Other Rights
	  	 	13	 
			
	5.	 	 COLLABORATION RESULTS
	  	 	13	 
				
		 	5.1	  	 Ownership
	  	 	13	 
				
		 	5.2	  	 Use [***] on Collaboration Results
	  	 	13	 
			
	6.	 	 CONFIDENTIALITY
	  	 	13	 
				
		 	6.1	  	 Duty of Confidence
	  	 	13	 
				
		 	6.2	  	 Exceptions
	  	 	13	 

  
 -i- 

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE
TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 TABLE OF CONTENTS 

(continued) 
  

									
				
	 	 	 	  	 	  	Page	 
				
		 	6.3	  	 Authorized Disclosures
	  	 	14	 
				
		 	6.4	  	 Terms of this Agreement
	  	 	14	 
				
		 	6.5	  	 CDA
	  	 	14	 
			
	7.	 	 PUBLICATIONS AND PUBLICITY
	  	 	14	 
				
		 	7.1	  	 Use of Names
	  	 	14	 
				
	    	 	7.2	  	 Publications
	  	 	14	 
			
	8.	 	 TERMINATION
	  	 	15	 
				
		 	8.1	  	 Termination
	  	 	15	 
				
		 	8.2	  	 Effects of Termination
	  	 	15	 
				
		 	8.3	  	 Survival
	  	 	15	 
			
	9.	 	 REPRESENTATIONS AND WARRANTIES
	  	 	16	 
				
		 	9.1	  	 Mutual Representations and Warranties
	  	 	16	 
				
		 	9.2	  	 No Other Warranties
	  	 	16	 
			
	10.	 	 LIMITATION OF LIABILITY
	  	 	16	 
			
	11.	 	 DISPUTE RESOLUTION
	  	 	16	 
				
		 	11.1	  	 Dispute Resolution
	  	 	16	 
				
		 	11.2	  	 Governing Law
	  	 	17	 
				
		 	11.3	  	 Exclusions
	  	 	17	 
				
		 	11.4	  	 Cumulative Remedies
	  	 	17	 
				
		 	11.5	  	 Waiver of Jury Trial
	  	 	18	 
			
	12.	 	 GENERAL PROVISIONS
	  	 	18	 
				
		 	12.1	  	 Assignment
	  	 	18	 
				
		 	12.2	  	 Extension to Affiliates
	  	 	18	 
				
		 	12.3	  	 Severability
	  	 	18	 
				
		 	12.4	  	 Force Majeure
	  	 	18	 
				
		 	12.5	  	 Waivers and Amendments
	  	 	19	 
				
		 	12.6	  	 Relationship of the Parties
	  	 	19	 
				
		 	12.7	  	 Notices
	  	 	19	 
				
		 	12.8	  	 No Third Party Beneficiary Rights
	  	 	20	 
				
		 	12.9	  	 English Language
	  	 	20	 
				
		 	12.10	  	 Entire Agreement
	  	 	20	 
				
		 	12.11	  	 Counterparts
	  	 	20	 

 EXHIBITS 

Exhibit A — Initial Research Plan 
 Exhibit B
— Initial Research Budget 
 Exhibit C — Financial Terms for Affinia’s Exercise of Its Option for an Exclusive License in the Non-Eye Field 

  
 -ii- 

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE
TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 SPONSORED RESEARCH COLLABORATION AGREEMENT 

This SPONSORED RESEARCH COLLABORATION AGREEMENT (this “Agreement” is made as of June 22, 2021 (the “Effective
Date”), by and between Affinia Therapeutics Inc., having its principal offices at 43 Foundry Ave., Suite 120, Waltham, MA 02453 (“Affinia”) and The Institute of Molecular and Clinical Ophthalmology Basel with
an address at Mittlere Strasse 91, CH-4031 Basel, Switzerland (“IOB”). Affinia and IOB are referred to individually as a “Party” and collectively as the
“Parties”. 
 RECITALS 

WHEREAS, IOB is a research foundation with the mission of advancing the understanding of
vision, its diseases, and developing new therapies for vision loss and has expertise in using, and possesses certain intellectual property rights in, and technology for researching and developing promoters for use in gene therapy; 

WHEREAS, Affinia is a gene therapy company with expertise in using, and possesses certain
intellectual property rights in, technology for engineering viral delivery vectors for gene therapy; and 

WHEREAS, Affinia desires to fund a research collaboration conducted by both Parties to
research and develop cell type-specific, tissue-specific, ubiquitous or other types of promoters useful in gene therapy, and IOB is willing to engage in such research collaboration funded by Affinia, in each case in accordance with the terms and
conditions of this Agreement. 
 NOW, THEREFORE, in consideration of the
mutual covenants and agreements herein contained, the receipt and sufficiency of which are hereby acknowledged, the Parties hereby agree as follows: 
  

	1.	 DEFINITIONS AND INTERPRETATION 

1.1 Definitions. Unless the context otherwise requires, the terms in this Agreement with initial letters capitalized, shall have
the meanings set forth below, or the meaning as designated in the indicated places throughout this Agreement. 

“Affiliate” means, with respect to a Party, any Person that controls, is controlled by, or is under common control
with that Party, but only for long as such control exists. For the purpose of this definition, “control” shall mean, the actual power, either direct or indirect through arrangement whereby the entity or person controls or has the right to
control the board of directors or equivalent governing body of a corporation or other entity, or the ability to cause the direction of the management or policies of a corporation or other entity. For the avoidance of doubt, none of the founding
entities of IOB are Affiliates of IOB. 
 “Affinia Materials” mean those specific tangible materials that are
proprietary to Affinia as described in the accompanying Material Transfer Sheet and provided for the purpose of conducting the Research Plan. 

“Affinia Patents” shall have the meaning set forth in Section 4.2(a) (Ownership). 

“Affinia Technology” means all Patents and Know-How Controlled by Affinia
(other than pursuant to a license under this Agreement) that are necessary to conduct the Research Plan Activities, including Affinia Materials. 

“Agreement” shall have the meaning set forth in the preamble. 

“Applicable Laws” mean those laws, rules, ordinances and regulations, whether federal (or national), state, local or
otherwise, that are enacted, promulgated, issued, enforced or entered into by any Governmental Authority applicable to any Party or such Party’s businesses, properties or assets. 

  
 1 

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE
TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 “Background IP” means, with respect to a Party, all Intellectual
Property Rights owned or Controlled by such Party as of the Effective Date or developed or acquired by such Party independently from the conduct of the Collaboration under this Agreement. 

“BLA” means a Biologic License Application, as defined in the United States Federal Food, Drug and Cosmetic Act, 21
U.S.C. §§ 301 et seq., and applicable regulations promulgated thereunder by the FDA, or any analogous application or submission with any Regulatory Authority outside of the United States. 

“Business Day” means any day that is not a Saturday, Sunday or other day on which commercial banks are authorized or
required to be closed, as the case may be, in Waltham, Massachusetts, New York City, New York, or Basel, Switzerland. 
 “Calendar
Quarter” means the respective periods of three (3) consecutive calendar months ending on March 31, June 30, September 30 and December 31, except that the first Calendar Quarter of the Research Term shall
commence on the Effective Date and the last Calendar Quarter shall end on the last day of the Research Term. 
 “CDA” means
that certain Mutual Confidentiality Agreement entered into by the Parties on [***]. 
 “cGLP” means the then-current
good laboratory practice as required by the FDA under 21 C.F.R. Part 58 and all applicable FDA rules, regulations, orders and guidances, and the applicable requirements with respect to current good laboratory practices prescribed by the European
Community, the OECD (Organization for Economic Cooperation and Development Council) and the ICH Guidelines, or the equivalent Applicable Law of an applicable Regulatory Authority. 

“Change of Control” shall have the meaning set forth in Section 12.1 (Assignment). 

“Clinical Study” means any study (including a non-interventional study) in
humans to obtain information regarding a product, including information relating to the safety, tolerability, pharmacological activity, pharmacokinetics, dose ranging or efficacy of the product. 

“Collaboration” shall have the meaning set forth in Section 2.1 (Scope). 

“Collaboration Inventions” mean all patentable Inventions conceived or first reduced to practice pursuant to the
conduct of the Research Plan Activities by or on behalf of the Parties during the Research Term. 
 “Collaboration
Results” mean, collectively, (a) all data, results, technical information, process information, protocols, procedures, reports, and other non-patentable Inventions arising or resulting
from and pursuant to the conduct of the Research Plan Activities during the Research Term, whether generated solely by or on behalf of a Party or jointly by or on behalf of the Parties and (b) [***]. 

“Collaboration Patents” mean (a) all Patents claiming any Collaboration Inventions and (b) [***]. 

“Confidential Information” means all Know-How, technical or strategic
information and other proprietary information and data of a financial, business, operational, scientific, or technical nature that is disclosed by or on behalf of a Party or any of its Affiliates or otherwise made available to the other Party or its
Affiliates or their representatives, in any form or medium (whether oral, visual, written, electronic, or otherwise), including information comprising or relating to Background IP and Materials, in each case, whether or not expressly identified as
“confidential”; provided further that the terms and conditions of this Agreement, the Joint Patents (until published), and all Collaboration Results shall constitute the Confidential Information of both Parties. 

  
 2 

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE
TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 “Control” or “Controlled” means, with respect to any
Intellectual Property Rights or any Confidential Information, the legal authority or right (whether by ownership, license or otherwise) of a Party to grant a license or a sublicense of or under such Intellectual Property Rights to another Person, or
to otherwise disclose such Confidential Information to another Person, without breaching the terms of any agreement with a Third Party or misappropriating the Confidential Information of a Third Party. 

“CREATE Act” shall have the meaning set further in Section 4.2(d) (CREATE Act). 

“Debarred Person” means a Person that is: (a) debarred from or disqualified under Applicable Laws or any other
governmental program; (b) on any of the FDA clinical investigator enforcement lists (including, the (i) Disqualified/Totally Restricted List, (ii) Restricted List and (iii) Adequate Assurances List); or (c) excluded from
participation in any governmental healthcare program or other federal or state program, convicted of an offense under 42 U.S.0 § 1320a-7, or otherwise deemed ineligible for participation in health care or
federal or state programs. 
 “Develop” means any and all clinical drug development activities conducted before obtaining
approval to market such drug from a Regulatory Authority that are reasonably related to or leading to the development, preparation, and submission of data and information to a Regulatory Authority for the purpose of obtaining such approval,
including all activities related to pharmacokinetic profiling, design and conduct of Clinical Studies, regulatory affairs, statistical analysis, report writing, and creating files to be submitted to a Regulatory Authority. For clarity, Develop shall
include [***]. 
 “Dispute” means any dispute, controversy, or claim between the Parties arising out of or relating to this
Agreement, including the validity, enforceability, interpretation, performance, breach, default or other noncompliance with this Agreement or any term or condition hereof, whether before or after termination of this Agreement, and including the
question of arbitrability and whether such dispute or claim would be barred by the applicable statute of limitations. 
 “Effective
Date” shall have the meaning set forth in the preamble. 
 “EMA” means the European Medicines Agency, or a
successor agency thereto. 
 “Eye Field” means any and all uses, modalities or applications for the treatment, diagnosis,
palliation, cure, restoration, or prevention of any diseases, disorders, symptoms or conditions affecting vision, [***]. For clarity, any such disease, disorder, symptom or condition that [***]. 

“FDA” means the United States Food and Drug Administration or any successor entity thereto. “Force Majeure Event”
shall have the meaning set forth in Section 12.4 (Force Majeure). 
 “FTE” means a
full-time person, or in the case of less than a full-time person, a full-time equivalent employee year, carried out by an employee of IOB or its Affiliates, based on [***] person-hours per calendar year. 

“FTE Costs” mean, for any period, the FTE Rate multiplied by the number of FTEs in such period. 

“FTE Rate” means the rate set forth on Exhibit B for the relevant IOB personnel costs. 

“Governing Law” shall have the meaning set forth in Section 11.2 (Governing Law). 

“Governmental Authority” means any applicable government authority, court, tribunal, arbitrator, agency, department,
legislative body, commission or other instrumentality of: (a) any government of any country or territory; (b) any nation, state, province, county, city or other political subdivision thereof; or (c) any supranational body. 

“ICC” shall have the meaning set forth in Section 11.1(b) (Rules). 

  
 3 

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE
TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 “ICC Rules” shall have the meaning set forth in
Section 11.1(b) (Rules). 
 “IND” means an investigational new drug application filed with
the FDA with respect to a pharmaceutical product, or an equivalent application filed with a Regulatory Authority in a country other than the United States to commence a Clinical Study of a pharmaceutical product. 

“Infringement” shall have the meaning set forth in Section 4.4 (Enforcement of Joint Patents). 

“Initial Term” shall have the meaning set forth in Section 2.2 (Research Term). 

“Intellectual Property Rights” mean any and all rights in and to any Know-How,
Patents, Trademarks, copyrights, trade secrets, and any other intellectual property rights however denominated throughout the world. 

“Invention” means any process, method, composition of matter, article of manufacture, discovery, improvement or Know-How that is generated, conceived and/or reduced to practice (whether patentable or not). 

“IOB” shall have the meaning set forth in the preamble of this Agreement. 

“IOB Materials” mean those specific tangible materials that are proprietary to IOB as described in the accompanying
Material Transfer Sheet and provided for the purpose of conducting the Research Plan. 
 “IOB Patents” shall have
the meaning set forth in Section 4.2(a) (Ownership). 
 “IOB Technology” means all Patents and Know-How Controlled by IOB (other than pursuant to a license under this Agreement) that are necessary to conduct the Research Plan Activities, including IOB Materials. 

“Joint Patents” shall have the meaning set forth in Section 4.2(a) (Ownership). 

“Joint Research Committee” or “JRC” shall have the meaning set forth in
Section 3.1 (Joint Research Committee). 
 “Know-How”
means all proprietary data, inventions, trade secrets and other information, in any tangible or intangible form, including databases, discoveries, practices, methods, tests, assays, techniques, specifications, processes, formulations, formulae, know-how, Materials, including pharmaceutical, chemical and biological materials and their sequences, protocols, procedures, drawings, plans, designs, diagrams, sketches, technology and documentation. 

“License Disagreement” shall have the meaning set forth in Section 4.6(b) (Non-Eye Field). 
 “Licensed Product” means any product that incorporates or comprises
any Licensed Promoter. 
 “Licensed Promoter” means (a) any promoter or other gene expression control or regulatory
element identified under and pursuant to the conduct of the Research Plan of the Collaboration during the Research Term (“Promoter”), or (b) any promoter or other gene expression control or regulatory element that [***], or
(c) any other promoter or other gene expression control or regulatory element that [***]. 
 “Material Transfer
Sheet” shall have the Meaning set forth in Section 2.10 (Materials). 

“Materials” mean any tangible compositions of matter, as well as any replication, copy, derivative, or progeny
developed or derived therefrom under the Collaboration. 

  
 4 

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE
TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 “Negotiation Period” shall have the meaning set forth in
Section 4.6(b) (Non-Eye Field). 

“Non-Eye Field” means any and all uses, modalities or applications for the
treatment, diagnosis, palliation, cure, or prevention of any diseases, disorders, symptoms or conditions in humans outside the Eye Field. 

“Non-Patented Promoters” mean those Promoters for which the Party owning such
Promoter in accordance with Section 4.2(a) (Ownership)[***] elects not to Prosecute and Maintain a Patent claiming such Promoter. 

“Offer” shall have the meaning set forth in Section 4.6(a) (Eye Field). 

“Option” shall have the meaning set forth in Section 4.6(b),
(Non-Eye Field). 
 “Option Period” shall have the meaning set forth in
Section 4.6(b) (Non-Eye Field). 
 “Party” or
“Parties” shall have the meaning set forth in the preamble of this Agreement. 
 “Patents” mean all
patents and patent applications, including all divisionals, continuations, substitutions, continuations-in-part, re-examinations,
reissues, additions, renewals, extensions, registrations, including patent term extensions and supplemental protection certificates and the like, utility models, design patents and the like of any of the foregoing in any country. 

“Person” means any individual, partnership, limited liability company, firm, corporation, association, trust,
unincorporated organization or other entity, including a Governmental Authority. 
 “Principal Investigator” shall
have mean IOB’s employee designated in accordance with Section 2.6 (Principal Investigator). 

“Prosecution and Maintenance” means, with regard to a particular Patent, the preparation, filing, prosecution and
maintenance of such Patent in any jurisdictions, as well as re-examinations, reviews, reissues and the like with respect to that Patent, together with the conduct of interferences, the defense of oppositions,
oppositions, post-grant reviews, inter partes reviews, and other similar proceedings with respect to that Patent and further including Patent management and litigation strategy. For clarity, [***]. 

“Public Disclosure” shall have the meaning set forth in Section 7.2 (Publications). 

“Regulatory Authority” means any Governmental Authority responsible for granting approval over pharmaceutical or biological
products, including the FDA, EMA, European Commission, and any corresponding national or regional regulatory authorities. 

“Research” means those activities related to the design, discovery, generation, identification, screening, evaluation,
analysis, profiling, characterization, optimization, production, process development, cell line development, pre-clinical research or pre-clinical development or non-clinical or pre-clinical studies of biopharmaceutical candidates and products, including such research, pre-clinical and non-clinical studies and other activities to be undertaken to generate data sufficient to enable the [***]. For clarity, [***]. 

“Research Budget” shall have the meaning set forth in Section 2.4 (Research Budget). 

“Research Costs” mean all FTE Costs and
out-of-pocket costs incurred by or on behalf of IOB in the performance of its Research Plan Activities in accordance with the then-current Research Plan. 

“Research Plan” means the written agreement setting forth the specific activities to be performed by or on behalf of
each Party to conduct the Collaboration. 

  
 5 

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE
TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 “Research Plan Activities” mean the activities allocated to each
Party (or a Third Party) under the Research Plan. 
 “Research Term” shall have the meaning set forth in
Section 2.2 (Research Term). 
 “Senior Officers” mean, for IOB, the [***], and for
Affinia, its [***], or in each case, another senior executive designee with responsibilities and seniority comparable thereto. 

“Third Party” means any Person other than a Party or an Affiliate of a Party. 

“Trademarks” mean all registered and unregistered trademarks, service marks, trade dress, trade names, logos,
insignias, symbols, designs, and all other indicia of ownership, and combinations thereof. 
 “Trigger Date” means,
(a) with respect to any Joint Patent that covers the Licensed Promoters, [***], and (b) with respect to any other Joint Patents, [***]. 

1.2 Interpretation. In construing this Agreement: (a) the terms “includes” and “including” shall mean
respectively includes and including without limitation; (b) any law, statue, or regulation, or any of their provisions shall be construed as a reference to such provision as the same may have been or may from time to time hereafter be amended
or re-enacted; (c) words denoting the singular shall include the plural and vice versa, and words denoting any gender shall include all genders; (d) exhibits and other attachments form part of the
operative provisions of this Agreement and references to this Agreement shall, unless the context otherwise requires, include references to the Exhibits and attachments; (e) the headings in this Agreement are for information and convenience
only and shall not be considered in the interpretation of or otherwise affect the meaning of this Agreement; (f) the word “days” refers to calendar days; (g) the terms “hereof,” “herein,” “hereby,”
and derivative or similar words refer to this entire Agreement and not any particular provision; (h) the word “or” is used in the inclusive sense (and/or), unless explicitly indicated otherwise by the term “either/or;” (i)
general words shall not be given a restrictive interpretation by reason of their being preceded-or followed by words indicating a particular class of acts, matters or things; (j) the words
“shall” and “will” have the same meaning and neither word shall be deemed to be more permissive than the other; and (k) the Parties agree that the terms and conditions of this Agreement are the result of negotiations
between the Parties and that this Agreement shall not be construed in favor of or against any Party by reason of the extent to which any Party participated in the preparation of this Agreement. 

 

	2.	 RESEARCH COLLABORATION 

2.1 Scope. During the Research Term, and in accordance with the terms and conditions of this Agreement, the Parties will
collaborate on the conduct of the Research Plan under and pursuant to which the Parties will design, identify, synthesize, optimize, and validate promoters for use in the cortex (the “Collaboration”). Upon a Party’s
request, the Parties will meet to discuss in good faith whether to expand the Collaboration to design, identify, synthesize, optimize or validate promoters for use in [***]. The Parties will document any such mutually agreed upon expansion to the
Collaboration as an amendment to this Agreement. 
 2.2 Research Term. This Agreement shall commence upon the Effective Date
and, unless earlier terminated in accordance with Section 8.1 (Termination), shall expire twenty-eight (28) months thereafter (the “Initial Term”), provided that the Initial Term may be extended
for additional [***] periods with the mutual written consent of the Parties, which written consent shall include updates to both the Research Plan and Research Budget (such period, as may be extended or shortened in accordance with this Agreement,
the “Research Term”). 
 2.3 Research Plan. The Parties have agreed upon a Research Plan, the initial version
of which is attached hereto as Exhibit A. During the Research Term, from time to time, and at least on a [***] basis, the Parties will jointly develop and submit, or either Party may propose for submission, updates or amendments to the
Research Plan for the JRC’s review and approval; provided that each such update or amendment to the Research Plan shall be consistent with the terms and conditions of this Agreement. 

 

  
 6 

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE
TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 2.4 Research Budget. The Parties have agreed upon an initial budget, which is
based upon IOB’s good faith estimate of the Research Costs to be incurred to perform its Research Plan Activities (the “Research Budget”), the initial version of which is attached hereto as Exhibit B. The Parties will
jointly develop and submit, or either Party may propose for submission, updates or amendments to the Research Budget for the JRC’s review and approval, provided that each such update or amendment shall fully cover all Research Costs to be
incurred by or on behalf of IOB under the Collaboration. 
 2.5 Conduct of Research Activities. Subject to the JRC’s
review and approval of any amendments to the Research Plan, the Parties will use [***] to perform (or subject to Section 2.7 (Subcontractors), have their permitted subcontractors perform) the Research Plan Activities in
accordance with the Research Plan. In performing its respective Research Plan Activities, each Party: (a) will conduct such activities in a good scientific manner, in compliance with all Applicable Law in all material respects, including, where
applicable, cGLP and current international regulatory standards; and (b) will not employ or use any Debarred Person. 
 2.6 Principal
Investigator. [***] will serve as the principal investigator of and will supervise the conduct of the Collaboration (the “Principal Investigator”). If Principal Investigator is unable to serve as principal
investigator of the Collaboration for any reason, IOB will promptly notify Affinia in writing of the same and propose one or more substitute principal investigators. The Parties will enter into good faith negotiations to identify a mutually
agreeable replacement, which replacement, if mutually agreed to by the Parties, will be deemed the “Principal Investigator” of the Collaboration. If the Parties fail to identify a mutually agreeable replacement within [***] following
IOB’s written notice, then either Party may terminate this Agreement upon written notice in accordance with Section 8.1 (Termination). 

2.7 Subcontractors. Each Party may subcontract certain Research Plan Activities to a qualified Third Party with the other
Party’s prior written approval, such approval not to be unreasonably delayed or withheld; provided, that: (a) each contract between a Party and a subcontractor is consistent with the provisions of this Agreement, including
obligations of [***]; and (b) the subcontracting Party remains responsible for the supervision of such subcontractor. For clarity, each Party approves the use of those Third Parties currently identified in the initial Research Plan. 

2.8 Research Records. Each Party will maintain, and cause its Affiliates and their respective employees and permitted
subcontractors to maintain, records and laboratory notebooks of its Research Plan Activities in sufficient detail and in a good scientific manner appropriate for scientific, regulatory and intellectual property protection purposes, which records and
laboratory notebooks shall: (a) be segregated from other activities not performed under this Agreement; and (b) be complete and accurate in all material respects. Each Party will timely provide copies of all such records or laboratory
notebooks in its possession or control to the requesting Party in a mutually agreed upon form, and at [***] expense. 
 2.9
Research Reports. Each Party will keep the other Party reasonably informed regarding the status, progress, and results of its Research Plan Activities through regularly scheduled JRC meetings, including providing a high level presentation
on the Research Results generated during such period. 
 2.10 Materials. In conducting the Research Plan Activities, each
Party may provide certain of its Materials to the other Party, the transfer of which shall be documented in writing by a material transfer sheet (“Material Transfer Sheet”) describing the IOB Materials or Affinia Materials, as applicable
being transferred and the amounts provided. The Parties acknowledge and agree that (a) all right, title, and interest in and to Affinia Materials, including all Intellectual Property Rights relating therein, is and shall remain vested in
Affinia ([***]), (b) all right, title, and interest in and to IOB Materials, including all Intellectual Property Rights relating therein, is and shall remain vested in IOB ([***]), (c) each Party will use the other Party’s Materials only to
conduct those Research Plan Activities expressly allocated to it under the Research Plan and in accordance with such Research Plan, (d) neither Party will transfer or deliver to or 

  
 7 

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE
TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 
for the benefit of any Third Party (other than permitted subcontractors in accordance with Section 2.7 (Subcontractors)) any Materials of the other Party without the prior
written consent of such other Party, and (e) neither Party will reverse engineer or attempt to determine the structure of any of the other Party’s Materials. Upon termination or expiration of this Agreement, each Party will, in accordance
with the owning Party’s instructions, either return or dispose of any Materials of the other Party in its possession or control. THE MATERIALS ARE PROVIDED “AS IS” AND WITHOUT ANY REPRESENTATION OR WARRANTY, EXPRESS OR IMPLIED,
INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY, SATISFACTORY QUALITY OR OF FITNESS FOR ANY PARTICULAR PURPOSE OR ANY WARRANTY THAT THE USE OF THE MATERIALS WILL NOT INFRINGE OR VIOLATE ANY PATENT OR OTHER PROPRIETARY RIGHTS OF ANY THIRD PARTY AND
EACH PARTY HEREBY DISCLAIMS ANY SUCH REPRESENTATIONS OR WARRANTIES. 
 2.11 Research Costs and Payment. 

(a) Research Costs. Affinia will be responsible for fully funding the conduct of all Research Plan Activities, whether performed by IOB,
Affinia, or any Third Party. Within [***] following each Calendar Quarter, IOB will invoice Affinia for all Research Costs incurred by or on behalf of IOB during such Calendar Quarter. Affinia will pay IOB all such Research Costs within [***] of
receipt of the applicable invoice. 
 (b) Other Amounts Payable. With respect to any amounts owed under this Agreement which no other
invoicing and payment procedure is specified, within [***] after the end of each Calendar Quarter, IOB will provide an invoice, together with reasonable supporting documentation, to Affinia for such amounts owed in respect of such Calendar Quarter.
Affinia will pay IOB all such amounts within [***] of receipt of the applicable invoice. 
 (c) Payment Terms. All payments hereunder
shall be made in Swiss Francs, without any withholding or other deductions for taxes, by wire transfer to such bank account as IOB may designate in writing. Any payments or portions thereof due hereunder which are not paid when due will bear
interest at the rate [***], calculated on the number of days such payment is paid after the date such payment is due, and [***]. 
  

	3.	 GOVERNANCE 

3.1 Joint Research Committee. Within [***] of the Effective Date, the Parties shall establish a joint research committee (the
“JRC”) to monitor and provide strategic oversight over the Collaboration. The JRC shall be responsible for: (a) discussing, preparing, and approving any amendments to the Research Plan or Research Budget;
(b) overseeing and directing the Research Plan Activities; (c) directing the strategic direction of the Collaboration; (d) reviewing and discussing all reports describing the Research Plan Activities and the Collaboration Results;
(e) reviewing and discussing the Parties’ Public Disclosures in accordance with Section 7.2 (Publications); (f) [***]; and (g) performing such other functions as may be appropriate to further the purposes of
this Agreement or as expressly provided in this Agreement. 
 3.2 Representatives and Meetings. 

(a) Representatives. Each Party shall initially appoint two (2) representatives to the JRC. The JRC may change its size from time
to time; provided, that the JRC shall consist at all times of an equal number of representatives of each of Affinia and IOB. Each JRC representative shall have appropriate knowledge and expertise and sufficient seniority ([***]) within the
applicable Party to make decisions arising within the scope of the JRC’s responsibilities. Each Party may replace its JRC representatives upon written notice to the other Party; [***]. 

  
 8 

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE
TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 (b) Chairpersons. Each Party shall appoint one (1) of its representatives to act
as a co-chairperson of the JRC. As of the Effective Date, IOB appoints [***] to serve as IOB’s chairperson and Affinia appoints [***] to serve as Affinia’s chairperson. The responsibility for running
each meeting shall alternate between the co-chairpersons from meeting-to-meeting, with [***] chairperson running the first
meeting. [***] chairperson shall prepare and circulate, with the approval of [***] chairperson: (i) agendas to the JRC representatives before each such meeting, and (ii) detailed minutes of each meeting for the JRC representative’s
review and approval. 
 (c) Meetings. The JRC shall hold meetings at such times as it elects to do so, but at least [***]. The
location of such meetings will alternate between locations designated by IOB and locations designated by Affinia. Meetings may be held in person or by audio or video teleconference. 

(d) Non-JRC Representatives. Each Party may invite a reasonable number of participants, in
addition to its representatives, to attend JRC meetings in a non-voting capacity where reasonably necessary to address the issues raised at the agenda for such meeting with the other Party’s prior written
consent; provided, that all such attendees shall be bound by obligations of confidentiality and non-disclosure no less stringent than those set forth in this Agreement. 

3.3 Resolution of Disputes. 

(a) All JRC decisions shall be made by unanimous vote, with each Party’s representatives collectively having one (1) vote. No
action taken at any meeting shall be effective unless at least two (2) JRC representatives of each Party are participating in such meeting. 

(b) The JRC will use [***] efforts to promptly resolve any such matter for which it has authority. If after reasonable discussion and
good-faith consideration of each Party’s view on a particular matter before the JRC and within the scope of its authority, the JRC representatives cannot reach an agreement as to such matter within [***] after such matter was brought to the JRC
for resolution, such disagreement shall be referred to the Senior Officers for resolution. 
 (c) If the Senior Officers cannot in
good faith resolve such matter within [***] after such matter has been referred to them, then subject to Section 3.3(d), the status quo will be maintained unless and until the Parties mutually agree on a resolution for such
matter; provided however that IOB shall not be obligated to undertake any Research Plan Activities which would exceed the Research Costs for such Research Plan Activities, unless Affinia agrees in willing to provide additional funding to reimburse
IOB for all Research Costs for such Research Plan Activities. 
 (d) Notwithstanding anything herein to the contrary, the JRC shall
have only the powers assigned expressly to it in this Article 3 (Governance) and shall not have any power to amend, modify or waive compliance with this Agreement. Each Party shall retain the rights, powers and discretion granted to it under
this Agreement, and matters that are specified in this Article 3 (Governance) only to be reviewed and discussed (as opposed to approved) do not require any agreement or decision by either Party and are not subject to the voting and
decision-making procedures set forth in this Section 3.3 (Resolution of Disputes). 
  

	4.	 INTELLECTUAL PROPERTY RIGHTS 

4.1 Background IP. 

(a) General. As between the Parties and except as expressly otherwise provided in Section 4.1(b) (Research
Term Licenses), neither Party will, as a result of this Agreement, acquire any right, title or interest in and to any Background IP of the other Party. 

(b) Research Term Licenses. Solely during the Research Term, (i) Affinia hereby grants to IOB, a limited, non-exclusive, sub-licensable (solely to IOB’s Affiliates or permitted subcontractors), worldwide license under Affinia Technology solely to the extent necessary to
conduct the Research Plan Activities assigned to IOB (or IOB’s Affiliates or permitted subcontractors) under and in accordance with the Research Plan and (ii) IOB hereby grants to Affinia, a limited,
non-exclusive, sub-licensable (solely to Affinia’s Affiliates or permitted subcontractors), worldwide license under IOB Technology solely to the extent necessary to
conduct the Research Plan Activities assigned to Affinia (or Affinia’s Affiliates or permitted subcontractors) under and in accordance with the Research Plan. 
  

  
 9 

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE
TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 (c) IOB Cooperation. During the Research Term and for a period of [***] thereafter,
if Affinia’s Development or commercialization of a Licensed Product in the Non-Eye Field would require a license under any Background IP of IOB within IOB Technology and Affinia has elected to exercise
its Option for an IOB Patent or Joint Patent in the Non-Eye Field, then (i) where IOB [***], and (ii) where IOB may [***]; in each case of (i) and (ii) for a period of up to [***], such period
to be extendable by the mutual written agreement of the Parties, from the date of Affinia’s request for such license, after which time IOB shall have no further obligations to Affinia. 

4.2 Collaboration Patents. 

(a) Ownership. Subject to Section 5.1 (Ownership), with respect to those Collaboration Inventions that become,
Collaboration Results, ownership of all Collaboration Patents shall be based on inventorship, as determined in accordance with the rules of inventorship under United States patent laws, and (i) Affinia shall solely own all right, title, and
interest in and to any Collaboration Patents made solely by its and its Affiliates’, employees, or independent contractors (“Affinia Patents”), (ii) IOB shall solely own all right, title, and interest in and to any
Collaboration Patents made solely by its and its Affiliates’, employees, or independent contractors (“IOB Patents”), and (iii) and the Parties shall jointly own with the other Party an undivided one-half right, title, and interest in any Collaboration Patents that are made jointly by employees, or independent contractors of one Party and its Affiliates together with employees, or independent contractors of
the other Party and its Affiliates (“Joint Patents”). Each Party hereby assigns to the other Party, one-half of its interest in and to the Joint Patents, including all rights of action and
claims for damages and benefits arising due to past and present infringement of said rights, such that each Party owns an undivided joint interest in and to such Joint Patents. Each Party shall and shall cause its Affiliates, employees, and
independent contractors to, execute and take such further actions reasonably necessary to effectuate such joint ownership in and to such Joint Patents. 

(b) Disclosure. IOB shall notify Affinia promptly in writing of any IOB Patents and Affinia shall notify IOB promptly in writing of all
Affinia Patents. Each Party shall promptly notify the other Party in writing of any Joint Patents and shall also timely respond to reasonable requests from the other Party for additional information regarding such Joint Patents. 

(c) Personnel Obligations. Each employee or independent contractor of a Party or its respective Affiliates performing work under this
Agreement shall, prior to commencing such work, be bound by assignment obligations, including: (i) promptly reporting any Invention and reporting any Intellectual Property Right arising from such work; (ii) presently assigning to the
applicable Party all of his or her right, title and interest in and to any Invention including all Intellectual Property Rights therein arising from such work (excluding any agreements with permitted subcontractors hereunder that are academic
universities and/or other governmental entities, for which a non-exclusive license, or an option for an exclusive license may be obtained); (iii) cooperating in the preparation, filing, prosecution,
maintenance, defense, and enforcement of any Patent; and (iv) performing all acts and signing, executing, acknowledging and delivering any and all assignments and other documents required for effecting the rights, obligations and purposes of
this Agreement. 
 (d) CREATE Act. Notwithstanding anything to the contrary in this Agreement, neither Party will have the right to
invoke the Cooperative Research and Technology Enhancement Act of 2004, 35 U.S.C. § 103(c)(2)-(c)(3) (the “CREATE Act”) when exercising its rights under this Agreement without the prior written consent of the other
Party[***]. In the event that a Party is permitted to invoke the CREATE Act as required by the preceding sentence, the Parties will cooperate and coordinate their activities with respect to any submissions, filings or other activities in support
thereof. The Parties acknowledge and agree that this Agreement is a “joint research agreement” as defined in the CREATE Act. 

  
 10 

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE
TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 4.3 Patent Prosecution and Maintenance of Collaboration Patents. 

(a) Responsibility. Subject to the terms and conditions of this Section 4.3 (Patent Prosecution and
Maintenance of Collaboration Patents), (i) IOB shall have the first right, but not the obligation, to Prosecute and Maintain the IOB Patents and Joint Patents, with its own patent counsel, which counsel shall be reasonably acceptable to Affinia with
respect to Joint Patents [***]; and (ii) Affinia shall have the right, but not the obligation to Prosecute and Maintain the Affinia Patents with its own patent counsel. If IOB decides not to Prosecute or Maintain (including, for clarity, a
decision by IOB not to initially file a Patent) either (A) [***] or (B) any Joint Patent, IOB shall promptly notify Affinia in writing, and Affinia shall thereupon have the right, but not the obligation, to
step-in and Prosecute and Maintain such [***] and such Joint Patent in both Parties’ name. For clarity, [***]. If Affinia elects to Prosecute and Maintain a Joint Patent and then later decides not to
Prosecute or Maintain such Joint Patent, then Affinia shall promptly notify IOB in writing, and IOB shall have the right, but not any obligations, to continue such Prosecution or maintenance in both Parties names, at Affinia’s expense; provided
however, that if Affinia elects to no longer pay the expenses for such Joint Patent, then IOB will have the right, but not the obligation, to continue to Prosecute and Maintain such Joint Patent in IOB’s name only and at IOB’s sole cost,
in which case Affinia will assign its joint interest in such Joint Patent to IOB. 
 (b) Costs and Cooperation. All costs and expenses
incurred by either Party to Prosecute and Maintain any Joint Patent shall be borne one hundred percent (100%) by Affinia if such Joint Patent has not been licensed by IOB for the Eye Field to any Third Party (with such costs and expenses pro-rated to reflect licensing of such Joint Patent to any Third Party for the Eye Field), and where IOB is the Prosecuting and Maintaining Party, it will invoice Affinia for those costs incurred to Prosecute and
Maintain any Joint Patents on a Calendar Quarterly basis. The Prosecuting and Maintaining Party will: (i) keep the other Party reasonably informed of the status of such Joint Patents; (ii) prior to making any filings or submissions or
responses to any Governmental Authority with respect to such Joint Patents, provide a copy thereof to the other Party and provide an adequate and timely opportunity as practicable given the circumstances for its review and comment;
(iii) consider in good faith all comments timely provided to the Prosecuting and Maintaining Party by the other Party on such filings and communications; and (iv) provide the other Party with copies of all filings or submissions to any
Governmental Authority with respect to such Joint Patents. Upon the Prosecuting and Maintaining Party’s request, the other Party shall provide the Prosecuting and Maintaining Party with all reasonable assistance and cooperation in connection
with its Prosecution and Maintenance of the applicable Joint Patents, including by providing access to relevant persons and executing all documentation reasonably requested by the Prosecuting and Maintaining Party. 

4.4 Enforcement of Joint Patents. If either Party becomes aware of any actual, threatened, or suspected infringement or other
violation by a Third Party of any Joint Patent (an “Infringement”), it shall promptly notify the other Party after becoming aware of such Infringement including providing all available evidence and details available concerning said
Infringement. The Parties shall thereafter consult and cooperate fully to determine a course of action, including the commencement of legal action to terminate any such Infringement; provided however, that neither Party may take any action with
respect to such potential Infringement without the other Party’s prior written consent. In addition, within [***] of the filing of a patent application for a Joint Patent, the Parties will negotiate in good faith on the terms for managing any
litigation involving such Joint Patent. 
 4.5 Use of [***] on Joint Patents. 

(a) General. Except [***], each Party shall be entitled to practice, license (through multiple tiers), assign (their respective interest
only) and otherwise exploit the Joint Patents in all countries and jurisdictions without the duty of accounting or seeking consent from the other Party. Solely to the extent necessary in any specific jurisdiction where required to give legal effect
to the rights to such Joint Patents, but subject to [***] and the rights of Affinia under Section 4.6 (Option Rights of Affinia) as provided under this Agreement, each Party hereby grants and agrees to grant to the other
Party a nonexclusive, royalty-free, fully-paid, worldwide, irrevocable, perpetual license, with the right to grant sublicenses through multiple tiers, to practice the Joint Patents for any and all purposes. 

  
 11 

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE
TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 (b) Eye Field. Notwithstanding Section 4.5(a) (General),
and on a Joint Patent-by-Joint Patent basis, for a period of [***] from the applicable Trigger Date for a Joint Patent, (i) IOB shall have the [***] right to [***]
in the Eye Field, [***], [***]; provided further, that [***]. Upon expiration of such [***] period, all such restrictions [***] shall expire, [***], and [***]. 

(c) Non-Eye Field. Notwithstanding Section 4.5(a) (General), and on a
Joint Patent-by-Joint Patent basis, for a period of [***] from the applicable Trigger Date for a Joint Patent, (i) Affinia shall have the [***] right to [***] in
the Non-Eye Field, [***]. Subject to Section 4.6 (Option Rights of Affinia), upon expiration of such [***] month period, all such restrictions [***] shall expire [***], and [***].

 4.6 Option Rights of Affinia. 

(a) Eye Field. IOB may, in IOB’s sole discretion, elect to grant Affinia the option to obtain a royalty-bearing license
under certain IOB Patents or Joint Patents, to Research, Develop, manufacture, use, sell, offer for sale, import, export, and commercialize Licensed Products for certain indications or modalities or applications within the Eye Field. If IOB elects
to offer Affinia any such option, IOB will provide Affinia with written notice of the same, including the scope of such license, and any time periods for Affinia to exercise its option or for the Parties to conclude negotiations on a license for
such option (the “Offer”). Affinia will have the right to exercise any such option within [***], or such longer period of time as mutually agreed by the Parties. If Affinia elects to exercise its option for such IOB Patent or Joint
Patent, as applicable, the Parties will negotiate in good faith the terms applicable to any such license for the time period set forth in the Offer, after which time, IOB shall have no further obligations to Affinia. 

(b) Non-Eye Field. Subject to Affinia’s full funding of the Research Plan Activities
and payment of all amounts due to IOB under this Agreement, IOB hereby grants Affinia, an exclusive option to acquire an exclusive (or if Affinia so elects, non-exclusive), worldwide, royalty-bearing license
[***] under IOB’s right, title and interest in and to any and all IOB Patents and Joint Patents and associated Collaboration Results, to Research, Develop, manufacture, use, sell, offer for sale, import, export, and commercialize Licensed
Products in the Non-Eye Field (the “Option”). Affinia shall have the right to exercise an Option for a period of [***] from the date of [***] such IOB Patent, or [***] a Joint Patent, as
applicable, unless otherwise extended by the mutual written agreement of the Parties (the “Option Period”). Upon Affinia’s exercise of an Option during the Option Period for such Option, the Parties shall engage in good faith
negotiations on the [***] terms and conditions of a license agreement covering such IOB Patent or Joint Patent (and associated Collaboration Results), as applicable, which license shall contain customary terms and obligations for the type of license
being granted, including diligence obligations, and in the case of an exclusive license, will contain the payment as are set forth on Exhibit C, [***]). If (i) Affinia either fails to respond to or elects not to exercise its Option for
such disclosed IOB Patent or Joint Patent, as applicable, within such Option Period, or (ii) IOB and Affinia fail to execute a license agreement for such IOB Patent or Joint Patent within [***] after the date of Affinia’s exercise of such
Option for such IOB Patent or Joint Patent within [***] after the date of Affinia’s exercise of such Option (or such longer period of time as may be agreed to by the IOB) (such period of time, the “Negotiation Period” and such
failure to agree upon the license, a “License Disagreement”), then in the case of each of (i) and (ii), except as provided in Section 4.7(a) (Grant to Affinia), IOB shall be free to license such IOB Patent or Joint Patent,
as applicable, in the Non-Eye Field to a Third Party without any further obligation to Affinia, [***]. 

4.7 Research and Development Licenses. 

(a) Grant to Affinia. If pursuant to Section 4.6(b) (Non-Eye Field),
Affinia was eligible to exercise an Option for an IOB Patent and the Parties failed to enter into a license agreement for such IOB Patent, then Affinia shall have, and IOB hereby grants Affinia, a fully-paid and royalty-free, non-exclusive, worldwide license under such IOB Patent, solely for Affinia’s Research and Development purposes in the Non-Eye Field, which license may be sublicensed to
Affinia’s Affiliates and Third Parties solely in furtherance of Affinia’s Research and Development activities. 

  
 12 

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE
TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 (b) Grant to IOB. To the extent that a license to any Affinia Patent is reasonably
necessary for IOB to [***], then IOB shall have, and Affinia hereby grants IOB, a fully-paid and royalty-free, non-exclusive, worldwide license under such Affinia Patent, solely for IOB’ s academic
Research and Development purposes in the Eye Field, which license is sublicensable solely to IOB’s Affiliates and [***] and solely in furtherance of IOB’s academic Research and Development activities[***]. 

4.8 No Other Rights. Each Party expressly reserves and retains all Patents, Know-How, or
other Intellectual Property Rights not expressly granted herein, and no right or license under any Patents, Know-How, or other Intellectual Property Rights of either Party is granted or shall be granted by
implication. 
  

	5.	 COLLABORATION RESULTS 

5.1 Ownership. All Collaboration Results shall be [***]. 

5.2 Use [***] on Collaboration Results. 

(a) Eye Field. Notwithstanding [***] ownership rights in and to the Collaboration Results, IOB shall have the [***] right to make, use,
[***] exploit, [***] Collaboration Results [***] in the Eye Field[***]. 
 (b) Non-Eye Field.
Notwithstanding [***] ownership rights in and to the Collaboration Results, Affinia shall have the [***] right [***] to make, use, [***] exploit, [***] Collaboration Results[***] in the Non-Eye Field, [***].
Notwithstanding [***] IOB shall have the right to[***] Collaboration Results[***] in the Non-Eye Field[***]. 

(c) Expiration. For clarity, subject to Section 4.6 (Option Rights of Affinia), the restrictions [***] use of
Collaboration Results (and the Intellectual Property Rights therein) as described above shall cease to apply with respect any specific Collaboration Results that either becomes publicly known or is otherwise made available pursuant to a Public
Disclosure made in accordance with Section 7.2 (Publication). 
  

	6.	 CONFIDENTIALITY 

6.1 Duty of Confidence. During the Research Term and for a period of [***] thereafter, and except as otherwise provided in this
Agreement or to exercise the rights that are expressly granted to a Party under this Agreement, each Party shall: (a) keep in confidence the Confidential Information of the other Party using the same degree of care with which such Party holds
its own confidential information and using at least a reasonable degree of care; (b) not disclose the Confidential Information of the other Party to any Third Party except as permitted by this Agreement; and (c) use the Confidential
Information of the other Party only to perform its obligations, exercise its rights, or as otherwise permitted under this Agreement. 

6.2 Exceptions. The obligations under this Article 6 (Confidentiality) shall not apply to any portion of any Confidential
Information that: 
 (a) is (at the time of disclosure) or becomes (after the time of disclosure) known to the public or part of the
public domain through no breach of this Agreement by the recipient Party; 
 (b) was known to, or was otherwise in the possession of,
the recipient Party prior to the time of disclosure by the disclosing Party as evidenced by written records; 
 (c) is disclosed to
the recipient Party on a non-confidential basis by a Third Party; or 
 (d) is independently
developed by or on behalf of the recipient Party without any use of or reference to the Confidential Information disclosed by the disclosing Party. 

  
 13 

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE
TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 6.3 Authorized Disclosures. Each Party may disclose Confidential Information of the
other Party: 
 (a) to its Affiliates and their respective directors, officers, employees, independent contractors including
consultants) and advisers, in each case, solely to the extent reasonably necessary for the purposes of conducting the Collaboration or exercising its rights under this Agreement, including obtaining approval of this transaction and the negotiation
and approval of any option rights hereunder; provided, that each such Person is bound by obligations of confidentiality and non-use to maintain the confidentiality of the Confidential Information in a manner
consistent with the confidentiality provisions of this Agreement; 
 (b) to the extent such use and disclosure is reasonably required
in the Prosecution and Maintenance of any Joint Patents undertaken in accordance with this Agreement; and 
 (c) to the extent such
disclosure is required by Applicable Laws, including the requirements of any Governmental Authority or Regulatory Authority or subject pursuant to the rules of any recognized stock exchange (but subject to Section 6.4
(Terms of this Agreement)); provided that the recipient Party: (i) informs the other Party as soon as reasonably practicable upon becoming aware of the required disclosure; (ii) at the disclosing Party’s request and expense, assists
such Party in attempting to object to, limit the required disclosure of, or seek a protective order for, such Confidential Information; and (iii) limits the disclosure to only that portion, which it is advised by counsel, to be legally required
lobe disclosed. For clarity, any such disclosure by the receiving Party shall not diminish the confidential and proprietary status of such Confidential Information except to the extent such Confidential Information falls within an exception between
Sections 6.2(a)- (d) (Exceptions). 
 6.4 Terms of this Agreement. Neither Party shall issue any press release or other public
statement, whether oral or written, disclosing the existence of this Agreement, or the terms hereof, without first obtaining the prior written consent of the other Party. In addition, except as otherwise permitted by this Article 6
(Confidentiality), neither Party shall disclose to any Third Party, whether orally or in writing, the existence of this Agreement or the terms and conditions of this hereof, without first obtaining the prior written consent of the other Party,
which consent in each case can be provided via email by the designated authorized legal representative of each Party. 
 6.5 CDA. As
of the Effective Date, this Agreement supersedes the CDA, and all “Confidential Information” (as defined in the Non-Disclosure Agreement) disclosed by or on behalf of a Party under the CDA shall be
deemed Confidential Information of such Party hereunder and shall be subject to the provisions of this Article 6 (Confidentiality). 
  

	7.	 PUBLICATIONS AND PUBLICITY 

7.1 Use of Names. Except as required by Applicable Laws or as provided for in this Article 7 (Publications and Publicity),
neither Party shall use the name or Trademark of the other Party or its Affiliates or their respective personnel in any press release, publication, or other form of public disclosure without first obtaining, in each case, the prior written consent
of the other Party ([***]). Subject to the foregoing, both Parties shall acknowledge Affinia’s support of the Collaboration in scientific publications and other scientific communications. 

7.2 Publications. If either Party desires to publish or present the Collaboration Results or any other information regarding the
Collaboration or the Research Plan Activities (each, a “Public Disclosure”), then such Party shall submit such proposed Public Disclosure to the other Party for its review at least [***] prior to its submission for publication or
presentation. Each Party shall also submit a copy of such proposed Public Disclosure at the same time to the JRC for its review and discussion. The publishing Party will, as reasonably requested by the
non-publishing Party within such [***] period, (a) delete from such proposed Public Disclosure any of the non-publishing Party’s Confidential Information
([***]), or (b) delay the submission of such proposed Public Disclosure for an additional period of up to [***] (not to exceed [***] from the date of submission of such proposed Public Disclosure to the other Party) in order to allow the non-publishing Party to pursue patent protection for any Collaboration Patents disclosed therein for which the non-publishing Party has the right to file or to request filing
of a patent application claiming such Collaboration Patent in accordance with Article 4 (Intellectual Property Rights). 

  
 14 

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE
TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

	8.	 TERMINATION 

8.1 Termination. 

(a) Termination for Breach. Either Party may terminate this Agreement for material breach by the other Party if such breach continues
uncured for a period of (i) [***] after receipt of notice thereof in the case of a failure to make any payment that is then due, or (ii) [***] in the case of any other type of asserted material breach. Termination of this Agreement pursuant to this
Section 8.1(a) (Termination for Breach) shall not affect any other rights or remedies which may be available to the non-defaulting Party. 

(b) Termination for Principal Investigator Departure. Either Party may terminate this Agreement upon written notice in the event the
Parties are unable to mutually agree on a replacement Principal Investigator in accordance with Section 2.6 (Principal Investigator). 

(c) Termination for Insolvency. Either Party may terminate this Agreement immediately upon written notice to the other Party if the
other Party if the other Party is judicially declared bankrupt, is unable to pay its bills as they become due, flies a petition under any bankruptcy or insolvency act or has any such petition filed against it that is not dismissed within [***]. 

(d) Termination by Affinia At Will. Commencing eighteen (18) months after the Effective Date, Affinia may terminate this Agreement
at will for any reason or for convenience at any time upon [***] prior written notice to IOB. IOB will take [***] during such [***] notice period to reduce any remaining costs and expenses to the extent reasonably practicable and each Party will
endeavor to wind down all of its Research Plan Activities as promptly as possible to the extent reasonably practicable. 
 8.2 Effects of
Termination. Upon any termination or expiration of this Agreement: 
 (a) The licenses granted by a Party under
Section 4.1(b) (Research Term Licenses) will terminate automatically; 
 (b) Within thirty (30) days of
the effective date of termination or expiration, as applicable, Affinia shall pay IOB for all unreimbursed Research Costs incurred by or on behalf of IOB as of the effective date of termination or expiration, as applicable, and any non-cancelable obligations committed under the Research Plan, whether for resources or personnel. 
 (c)
Each Party will, in accordance with the owning Party’s instructions, either return or destroy all Confidential Information of the other Party, including all copies thereof and all materials containing such Confidential Information within
[***] of such termination or expiration (and provide certification of such destruction to the owning Party); provided, that: (i) a Party may retain one (1) copy of certain written materials containing Confidential Information of the
other Party in its archives solely for the purpose of monitoring its ongoing confidentiality obligations hereunder; and (ii) a Party will not be obligated to destroy any Confidential Information or any such written materials containing
Confidential Information of the other Party that are necessary for the Party to exercise any other license or right of such Party that survives such termination or expiration of this Agreement; and 

(d) Except as set forth in Section 8.3 (Survival), the rights and obligations of the Parties hereunder shall
terminate as of the date of such termination. 
 8.3 Survival. Expiration or termination of this Agreement shall not relieve
the Parties of any obligation accruing prior to such expiration or termination. The following Articles and Sections shall survive any expiration or termination of this Agreement for any reason for the period of time specified therein, or if not
specified, then they will survive indefinitely: [***]. 

  
 15 

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE
TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

	9.	 REPRESENTATIONS AND WARRANTIES 

9.1 Mutual Representations and Warranties. Each Party represents and warrants to the other Party, that as of the Effective Date:
(a) such Party is a company or institution, duly organized, validly existing, and in good standing under the laws of its jurisdiction of formation or incorporation; (b) such Party has full right, power, and authority to execute and deliver
this Agreement, to grant the rights and licenses granted hereunder, and to perform its obligations hereunder and has taken all action required by Applicable Law and its organizational documents to authorize the execution and delivery of this
Agreement by such Party and the performance of all obligations of such Party as contemplated by this Agreement; (c) it will carry out its obligations and activities under this Agreement and under the Research Plan hereunder in accordance with
all Applicable Laws in all material respects[***]; and (d) this Agreement constitutes a legal, valid, and binding agreement enforceable against such Party in accordance with its terms. 

9.2 No Other Warranties. EXCEPT AS OTHERWISE EXPRESSLY SET FORTH HEREIN, NEITHER PARTY MAKES ANY REPRESENTATIONS OR WARRANTIES, EXPRESS
OR IMPLIED, CONCERNING ANY MATTER WHATSOEVER REGARDING THE COLLABORATION, INCLUDING WITH RESPECT TO THE COLLABORATION RESULTS OR INVENTIONS GENERATED IN THE CONDUCT OF THE COLLABORATION OR THE OWNERSHIP, MERCHANTABILITY OR FITNESS FOR A PARTICULAR
PURPOSE OF SUCH COLLABORATION RESULTS OR INVENTIONS. NEITHER PARTY MAKES ANY REPRESENTATIONS OR WARRANTIES THAT THE CONDUCT OF THE RESEARCH PLAN WILL PRODUCE ANY SPECIFIC OR DESIRED RESULT OR BE COMPLETED WITH ANY PROJECTED TIME PERIOD. 

 

	10.	 LIMITATION OF LIABILITY 

EXCEPT [***] SHALL BE LIABLE TO [***] FOR ANY SPECIAL, CONSEQUENTIAL, INCIDENTAL, PUNITIVE, OR INDIRECT DAMAGES ARISING OUT OF OR RELATED TO THIS AGREEMENT FOR
ALL CAUSES OF ACTION OF ANY KIND (INCLUDING TORT, CONTRACT, NEGLIGENCE, STRICT LIABILITY AND BREACH OF WARRANTY) EVEN IF ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. EXCEPT FOR [***], [***] AGGREGATE LIABILITY TO [***], TOGETHER WITH THE LIABILITY OF
ANY OF ITS OFFICERS, DIRECTORS, TRUSTEES, EMPLOYEES, OR AGENTS, IN CONNECTION WITH THIS AGREEMENT SHALL NOT EXCEED [***] AT THE TIME SUCH CLAIM AROSE. 
  

	11.	 DISPUTE RESOLUTION 

11.1 Dispute Resolution. Subject to Section 11.3 (Exclusions), any unresolved Disputes shall be resolved by
final and binding arbitration as follows: 
 (a) Notice. Whenever a Party decides to institute arbitration proceedings for unresolved
Dispute between the Parties including any Dispute that is subject to the authority of the JSC and that is not resolved after escalation to the Senior Officers pursuant to the provisions of Section 3.3 (Resolution of
Disputes), it shall as promptly as possible give written notice to that effect to the other Party. 
 (b) Rules. The arbitration shall
be administered by the International Chamber of Commerce (the “ICC”) and conducted according to the Rules of Arbitration of the International Chamber of Commerce (the “ICC Rules”), except that to the extent the ICC Rules conflict
with or are otherwise inconsistent with the terms in this Article 11 (Dispute Resolution), then the terms of this Article 11 (Dispute Resolution) shall control and prevail. The arbitration panel shall be guided by the IBA Rules on the
Taking of Evidence in International Arbitration. 

  
 16 

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE
TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 (c) Panel Appointment. The arbitration will be conducted by a panel of three
(3) arbitrators, each of whom shall be fluent in English. Each Party shall nominate an arbitrator pursuant to the ICC Rules, and such arbitrators shall together, in consultation with the Party who appointed them, within [***] of their
appointment, select a third arbitrator as the chairperson of the arbitration panel. If either Party fails to appoint an arbitrator as provided above of the two Party-appointed arbitrators are unable to select a thud arbitrator within the time period
provided above, then such arbitrator(s) shall be appointed in accordance with the ICC Rules. No potential arbitrator shall be appointed unless such individual has agreed in writing to abide and be bound by the provisions of this Agreement. 

(d) Seat. The arbitration shall be seated in [***]. Any in-person proceedings may be held in any
location directed by the arbitral panel or otherwise agreed by the Parties. 
 (e) Language. All proceedings, including all evidence,
whether written or oral, shall be conducted in the English language, without prejudice to the right of any party to present witness testimony in the witness’s native language through an interpreter. There shall be a stenographic record of the
proceedings. 
 (f) Ruling. The arbitral panel will render a written award setting forth findings of fact and conclusions of law on
each issue. The arbitrators shall render their opinion within [***] of the final arbitration hearing. Awards of the panel of arbitrators shall be based on the application of Governing Law in accordance with Section 11.2
(Governing Law) and, unless in violation of this Agreement, shall be final and binding on the Parties. Judgment on any award so rendered may be entered in any court of competent jurisdiction and the Parties hereby consent to the jurisdiction of such
court for purposes of enforcement of such award. No arbitrator (nor the panel of arbitrators) shall have the power to award damages in violation of or that otherwise exceed the limits set forth in Article 10 (Limitation of Liability) of this
Agreement and such an award is expressly prohibited. 
 (g) Fees. The costs and expenses of the arbitration, including the
Parties’ reasonable attorneys’ fees, will be borne by [***]. 
 (h) Confidentiality. The existence of any proceedings and
all submissions, correspondence and evidence relating to such arbitration including the final award shall be confidential, and except in a proceeding to confirm an award or as otherwise required by Applicable Laws, neither Party nor any arbitrator
may disclose the existence, content, or results of any arbitration hereunder without the prior written consent of both Parties. 
 11.2
Governing Law. This Agreement shall be governed by and construed under the laws of the State of New York, U.S., without giving effect to the conflicts of laws provision thereof (“Governing Law”). The United Nations
Convention on Contracts for the International Sale of Goods (1980) shall not apply to the interpretation of this Agreement. 
 11.3
Exclusions. Notwithstanding Section 11.1 (Dispute Resolution), each Party may (a) seek injunctive or other interim or equitable relief from any court of competent jurisdiction to enforce and prevent infringement of
Intellectual Property Rights owned or controlled by a Party or to prevent other breach or threatened breach of this Agreement, (b) submit any Dispute relating to the scope, validity, inventorship, enforceability or infringement of any
Intellectual Property Right before any administrative body in the country in which such Intellectual Property Right was granted or in a court of competent jurisdiction, and (c) bring any Dispute regarding an alleged violation of any antitrust,
anti-monopoly or competition law or regulation, whether or not statutory, in either case, in a court of competent jurisdiction, in each case of (a) through (c) without first submitting to the dispute resolution procedures set forth in this
Section 11.3 (Exclusions). For the avoidance of doubt, any Dispute as to whether a Dispute falls within the exclusions in this Section 11.3 (Exclusions) shall be determined by the arbitration
panel, deciding such issue as a preliminary matter on an expediated basis. 
 11.4 Cumulative Remedies. No remedy referred to in this
Agreement is intended to be exclusive, but each shall be cumulative and in addition to any other remedy referred to in this Agreement or otherwise available under Applicable Laws. 

 

  
 17 

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE
TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 11.5 Waiver of Jury Trial. TO THE EXTENT NOT PROHIBITED BY APPLICABLE LAW THAT CANNOT
BE WAIVED, THE PARTIES HEREBY WAIVE, AND COVENANT THAT THEY WILL NOT ASSERT (WHETHER AS PLAINTIFF, DEFENDANT OR OTHERWISE), ANY RIGHT TO TRIAL BY JURY IN ANY ACTION ARISING IN WHOLE OR IN PART UNDER OR IN CONNECTION WITH THIS AGREEMENT, WHETHER NOW
EXISTING OR HEREAFTER ARISING, AND WHETHER SOUNDING IN CONTRACT, TORT, OR OTHERWISE. THE PARTIES AGREE THAT ANY OF THEM MAY FILE A COPY OF THIS PARAGRAPH WITH ANY COURT AS WRITTEN EVIDENCE OF THE KNOWING, VOLUNTARY AND
BARGAINED-FOR AGREEMENT AMONG THE PARTIES IRREVOCABLY TO WAIVE ITS RIGHT TO TRIAL BY JURY IN ANY PROCEEDING WHATSOEVER BETWEEN THEM RELATING TO THIS AGREEMENT WILL INSTEAD BE TRIED IN A COURT OF COMPETENT
JURISDICTION BY A JUDGE SITTING WITHOUT A JURY. 
  

	12.	 GENERAL PROVISIONS 

12.1 Assignment. [***] may assign its rights and obligations under this Agreement, in whole or part, without [***] prior express written
consent, except that Affinia may assign this Agreement in the entirety without the requirement to obtain the consent of IOB but upon written notice, if the assignment by Affinia is to (a) any successor or transferee in interest in the case of
any merger, consolidation, sale or other change of control of Affinia, or the transfer or sale of all or substantially all of the assets or business of Affinia relating to the subject matter of this Agreement (collectively, a “Change of
Control”), or (b) any of its Affiliates but only for so long as such Affiliate remains an Affiliate and provided further than any assignment to an Affiliate must be assigned back to Affinia in the event that such Person no longer meet
the definition of an Affiliate. Any permitted assignee will assume all obligations of its assignor under this Agreement (or related to the assigned portion in case of a partial assignment). In the event that [***], IOB will [***]. If at any time
[***]. For clarity, any subcontracting of any rights or obligations under this Agreement shall be governed by Section 2.7 (Subcontractors). Any attempted assignment or transfer in contravention of the foregoing will be
void. Subject to the terms of this Agreement, this Agreement will be binding upon and inure to the benefit of the Parties and their respective permitted successors and assigns. 

12.2 Extension to Affiliates. Each Party may discharge any obligations and exercise any rights under this Agreement through
delegation of its obligations or rights to any of its Affiliates. Each Party hereby guarantees the performance by its Affiliates of such Party’s obligations under this Agreement, and will cause its Affiliates to comply with the provisions of
this Agreement in connection with such performance. Any breach by a Party’s Affiliate of any of such Party’s obligations under this Agreement will be a breach by such Party, and the other Party may proceed directly against such Party
without any obligation to first proceed against such Party’s Affiliate. 
 12.3 Severability. Should one or more of the
provisions of this Agreement become void or unenforceable as a matter of law, then this Agreement shall be construed as if such provision were not contained herein and the remainder of this Agreement shall be and remain in full force and effect, and
the Parties will use their commercially reasonable efforts to substitute for the invalid or unenforceable provision a valid and enforceable provision that conforms as nearly as possible with the original intent of the Parties. 

12.4 Force Majeure. Neither Party will be liable or responsible to the other Party nor deemed to have defaulted under or breached
this Agreement for any failure or delay in fulfilling or performing any obligation, other than an obligation to make payments hereunder, to the extent such failure or delay is caused by or results from fire, floods, or acts of nature such as
hurricanes, earthquakes, or tsunamis, embargos, shortages in supplies or energy, any actions of Governmental Authorities, including any prohibitions or interventions, war, acts of war (whether declared or not), insurrections, riots, civil
commotions, strikes, terrorism, acts of God or any other cause beyond the reasonable control of the affected Party to prevent or avoid (each, a “Force Majeure Event”); provided, that the affected Party (a) provides prompt
written notice to the other Party of such Force Majeure Event and the resulting failure or delay, (b) uses reasonable efforts to mitigate the effects of the force Majeure Event, and (c) promptly resumes performance upon cessation of the
Force Majeure Event. 

  
 18 

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE
TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 12.5 Waivers and Amendments. The delay or failure of any Party to assert a
right hereunder or to insist upon compliance with any term or condition of this Agreement shall not constitute a waiver of that right or excuse a similar subsequent failure to perform any such term or condition by the other Party, and no waiver
shall be effective unless it has been given in writing and signed by the Party giving such waiver. No waiver by either Party of any condition or of the breach of any term contained in this Agreement, in any one or more instances, will be deemed to
be, or considered as, a further or continuing waiver of any such condition or of the breach of such term or any other term of this Agreement. No provision of this Agreement may be amended or modified other than by a written document signed by
authorized representatives of each Party. 
 12.6 Relationship of the Parties. Nothing contained in this Agreement shall be
deemed to constitute a partnership, joint venture, or legal entity of any type between Affinia and I0B, or to constitute one as the agent of the other. Moreover, each Party agrees not to construe this Agreement, or any of the transactions
contemplated hereby, as a partnership for any tax purposes. Each Party shall act solely as an independent contractor, and nothing in this Agreement shall be construed to give any Party the power or authority to act for, bind, or commit the other
Party. 
 12.7 Notices. Except with respect to payment, which shall be directed to such address as provided for under
Section 2.11(c) (Payment Terms), all notices, consents, and other communications under this Agreement must be in writing and will be deemed to have been duly given when: (a) delivered by hand (with written confirmation
of receipt); or (b) when received by the addressee, if sent by an internationally recognized overnight delivery service (receipt requested), in each case, to the appropriate addresses set forth below (or to such other addresses as a Party may
designate by notice in accordance with this Section 12.7 (Notices)). In addition, each Party may send a courtesy copy of such notice by electronic mail to the other Party, which copy shall not be used for the purpose of
determining notice. 
 If to Affinia: 

Affinia Therapeutics, Inc. 
 43
Foundry Ave., Suite 120 
 Waltham, MA, USA 02453 

Attn: [***] 
 e-mail: [***] 
 with a copy to: 

Affinia Therapeutics, Inc. 
 43
Foundry Ave., Suite 120 
 Waltham, MA, USA 02453 

Attn: [***] 
 e-mail: [***] 
 If to IOB: 

The Institute of Molecular and Clinical Ophthalmology Basel 

Mittlere Strasse 91 
 CH-4031 Basel, Switzerland 
 Attn: [***] 

e-mail: [***] 

with a copy to: 
 The Institute
of Molecular and Clinical Ophthalmology Basel 
 Mittlere Strasse 91 

CH-4031 Basel, Switzerland 

Attn: [***] 
 e-mail: [***] 

  
 19 

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE
TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 Any such notice shall be deemed to have been given on the Business Day received, subject to
proof of receipt, as evidenced by the date noted on the applicable courier’s receipt (or if delivered or sent on a non-Business Day, then on the next Business Day). 

12.8 No Third Party Beneficiary Rights. The provisions of this Agreement are for the sole benefit of the Parties and their successors
and permitted assigns, and they shall not be construed as conferring any rights to any Third Party (including any third party beneficiary rights). 

12.9 English Language. This Agreement is written and executed in the English language. Any translation into any other language shall not
be an official version of this Agreement and in the event of any conflict in interpretation between the English version and such translation, the English version shall prevail. 

12.10 Entire Agreement. This Agreement, together with its Exhibits, which are incorporated by reference herein, sets forth the entire
agreement and understanding of the Parties as to the subject matter hereof and supersedes all agreements, proposals, oral or written, and all other prior communications between the Parties with respect to such subject matter, including the CDA. In
the event of any conflict between a substantive provision of this Agreement and any Exhibit hereto, the substantive provisions of this Agreement shall prevail. 

12.11 Counterparts. This Agreement may be executed in one or more counterparts, each of which shall be deemed an original, but all of
which together shall constitute one and the same instrument. Signature pages of this Agreement may be exchanged by email/pdf or other electronic means without affecting the validity thereof. 

[***] 

  
 20 

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE
TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 IN WITNESS WHEREOF, the Parties intending to be bound have caused this Agreement to
be executed by their duly authorized representatives as of the Effective Date. 
  

					
	INSTITUTE OF MOLECULAR AND CLINICAL OPHTHALMOLOGY BASEL	 	                        	  	AFFINIA THERAPEUTICS, INC.
			
	By: /s/
[***]                                        
                            	 		  	By: /s/
[***]                                        
                                
	Name: [***]	 		  	Name: [***]
	Title: Director of Operations	 		  	Title: Chief Legal Officer
			
	Date: June 24, 2021	 		  	Date: June 22, 2021
			
	By: /s/
[***]                                        
                            	 		  	
	Name: [***]	 		  	
	Title: Director	 		  	
			
	Date: June 24, 2021	 		  	

  
 [Signature Page to
Sponsored Research Collaboration Agreement] 
 [ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN
OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 Exhibit A 

Initial Research Plan 

[***] 

  
 [ *** ] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 Exhibit B 

Initial Research Budget 

[see attached]     

  
 [ *** ] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 [***] 

  
 [ *** ] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 Exhibit C 

Financial Terms for Affinia’s Exercise of Its Option for 

an Exclusive License in the Non-Eve Field 

$100.000 USD Initial License Fee 
 [***] 

  
 [ *** ] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.EX-10.6

 Exhibit 10.6 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND
(II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 
  
 

 
 MANUFACTURING SERVICES AGREEMENT 

THIS MANUFACTURING SERVICES AGREEMENT (the
“Agreement”) is made as of April 30th 2021 (the “Effective Date”) between LONZA HOUSTON, INC.
located at 14905 Kirby Drive, Houston, TX 77047 (“LONZA”), and AFFINIA THERAPEUTICS, INC., a Delaware corporation with a place of business at 43 Foundry Ave., Suite 120,
Waltham, MA 02453 (“CLIENT”), (each of LONZA and CLIENT, a “Party” and, collectively, the “Parties”). 

RECITALS 

A. LONZA operates a multi-client production facility located at 14905 Kirby Drive, Houston, TX 77047, and/or such other location as
LONZA may designate in writing from time to time (the “Facility”). 
 B. CLIENT desires to have LONZA produce
one or more products intended for therapeutic use in humans, and LONZA desires to produce such products. 
 C. CLIENT desires to have
LONZA conduct work according to one or more individual Statements of Work, as further defined below. 
 NOW,
THEREFORE, in consideration of the foregoing and the mutual promises and covenants hereinafter set forth, LONZA and CLIENT, intending to be legally bound, hereby agree as follows: 

AGREEMENT 
 1.
DEFINITIONS 
 When used in this Agreement, capitalized terms will have the meanings as defined below and throughout the
Agreement. Unless the context indicates otherwise, the singular will include the plural and the plural will include the singular. 

1.1 “Acceptance Period” shall have the meaning set forth in Section 5.2. 

1.2 “Affiliate” means, with respect to either Party, any other corporation or business entity that directly, or
indirectly through one or more intermediaries, controls, is controlled by or is under common control with such Party. For purposes of this definition, the term “control” and, with correlative meanings, the term “controlled by”
and “under common control with” means direct or indirect ownership of more than fifty percent (50%) of the securities or other ownership interests representing the equity voting stock or general partnership or membership interest of such
entity or the power to direct or cause the direction of the management or policies of such entity, whether through the ownership of voting securities, by contract, or otherwise. 

1.3 “Background Intellectual Property” means any intellectual Property either (i) owned or controlled by a
Party prior to the Effective Date or (ii) developed or acquired by a Party independently from performance under this Agreement during the term of the Agreement, except that, the LONZA Background Intellectual Property shall exclude any
Intellectual Property that was licensed by CLIENT from LONZA under the Exclusive License Agreement (as defined below), as such licensed Intellectual Property shall be deemed to be included under the CLIENT Background Intellectual Property for all
purposes under this Agreement. 
 1.4 “Batch” means a specific quantity of Product that is intended to have
uniform character and quality, within specified limits, and is produced according to a single manufacturing order during the same cycle of manufacture. 

1.5 “Batch Record” means the production record pertaining to a Batch. 

  
 1 

 1.6 “cGMP” or “GMP” means the
applicable regulatory requirements, as amended from time to time, for current good manufacturing practices, including without limitation those promulgated by (i) the FDA under the United States Federal Food, Drug and Cosmetic Act,
21 C.F.R. § 210 et seq., or (b) the European Medicines Agency or under the European Union guide to good manufacturing practice for medicinal products. 

1.7 “cGMP Batch” means any Batch which is required under the Statement of Work to be manufactured in accordance
with cGMP. 
 1.8 “Change Order” has the meaning set forth in Section 2.2. 

1.9 “CLIENT Development Materials” has the meaning set forth in Section 2.3. 

1.10 “CLIENT Inventions” means any know-how, media, assays, methods or
other inventions, whether or not patentable, conceived, developed or reduced to practice by CLIENT: (a) on or before the Effective Date; or (b) in connection with the performance of the Statement of Work. 

1.11 “CLIENT Materials” means the CLIENT Development Materials and the CLIENT Production Materials. 

1.12 “CLIENT Personnel” has the meaning set forth in Section 4.8.1. 

1.13 “CLIENT Production Materials” has the meaning set forth in Section 4.1. 

1.14 “Commencement Date” means the date set forth in the Statement of Work for the commencement of Services,
including the production of the Product. 
 1.15 “Confidential Information” has the meaning set forth in
Section 10.1. 
 1.16 “Disapproval Notice” shall have the meaning set forth in Section 5.2. 

1.17 “Engineering Batch” means a Batch that is intended to demonstrate the transfer of the Process to the
Facility. 
 1.18 “FDA” means the U.S. Food and Drug Administration, and any successor agency thereof. 

1.19 “First Statement of Work” has the meaning set forth in the definition of Statement of Work. 

1.20 “Intellectual Property” means all worldwide patents, copyrights, trade secrets, know-how and all other intellectual property rights, including all applications and registrations with respect thereto, but excluding all trademarks, trade names, service marks, logos and other corporate
identifiers. 
 1.21 “LONZA Inventions” means any know-how, media,
assays, methods or other inventions, whether or not patentable, conceived, developed or reduced to practice by LONZA: (a) on or before the Effective Date; or [***]. 

1.22 “LONZA Operating Documents” means the standard operating procedures, standard manufacturing procedures,
raw material specifications, protocols, validation documentation, and supporting documentation used by LONZA, such as environmental monitoring, for operation and maintenance of the Facility and LONZA equipment used in the process of producing the
Product, excluding any of the foregoing that are unique to the manufacture of Product. 
 1.23 “LONZA
Parties” has the meaning set forth in Section 15.2. 

  
 2 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 1.24 “Materials” means all raw materials and supplies to be
used in the production of a Product. 
 1.25 “Process” means the manufacturing process for a Product. 

1.26 “Product” has the meaning set forth in a Statement of Work. 

1.27 “Product Warranties” means those warranties as specifically stated in Section 5.1. 

1.28 “Project Documentation” means the compilation of documentation generated by LONZA in preparation of and
during the performance of a given SOW, including, without limitation, executed Batch Records, the Process description as agreed to by LONZA and CLIENT to be used for the applicable SOW, component records, test records and test record forms,
certificates of analysis, study protocols, study summary reports, deviation reports, laboratory investigations, environment excursions, formulation records, and other related documents. 

1.29 “Regulatory Approval” means the approval [***] to market and sell the Product in the respective markets.

 1.30 “Services” means the activities to be performed by Lonza under a Statement of Work. 

1.31 “SOP” means a standard operating procedure. 

1.32 “Specifications” means the Product specifications set forth in the certificate of analysis or as modified
by the Parties, in writing, in connection with the production of a particular [***] Batch of Product hereunder. 
 1.33
“Statement of Work” or “SOW” means a plan to develop a Process or Product that is attached hereto as Appendix A or later becomes attached through an amendment by the Parties. The first Statement
of Work, which is attached hereto, is numbered Appendix A-1 and is hereby incorporated and made a part of this Agreement (the “First Statement of Work”). It is contemplated that
each separate project shall have its own Statement of Work. As each subsequent Statement of Work is agreed to by the Parties, each shall state that it is to be incorporated and made a part of this Agreement and shall be consecutively numbered as A-2, A-3, etc. 
 1.34 “Technology
Transfer” means the transfer of documentation, Specifications, and production process by CLIENT to LONZA and by LONZA to CLIENT for the development of the Project Documentation for the manufacture of the Product [***] for the CLIENT.

 1.35 “Third Party” means any party other than LONZA, CLIENT or their respective Affiliates. 

2. STATEMENTS OF WORK—PROCESS AND PRODUCT
DEVELOPMENT; PROCESS OR PRODUCT MANUFACTURE 
 2.1
Statement of Work. Prior to performing any Process or Product development, Technology Transfer, or Process or Product manufacture, the Parties will collaborate to develop a Statement of Work, describing the activities to be performed by the
Parties, or to be subcontracted by LONZA to Third Parties. In the event of a conflict between the terms and conditions of this Agreement and any Statement of Work, the terms and conditions of this Agreement shall control. For each given SOW, the
specific Project Documentation (either by original or copy) and the Product that will be provided to client will be described in each SOW. Client shall own such Product in accordance with the terms set forth in Section 4.6 of the Agreement and
shall own the copies of the Project Documentation provided to it by LONZA. 

  
 3 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 2.2 Modification of Statement of Work. Should CLIENT want to change a
Statement of Work or to include additional services to be provided by LONZA, CLIENT may propose to LONZA an amendment to the Statement of Work with the desired changes or additional services (“Change Order”). If LONZA
determines that it has the resources and capabilities to accommodate such Change Order, LONZA will prepare a modified version of the Statement of Work reflecting such Change Order (including, without limitation, any changes to the estimated timing,
estimated charges or scope of a project) and will submit such modified version of the Statement of Work to CLIENT for review and comment. The modified Statement of Work shall be binding on the Parties only if [***] and is signed by both Parties.
Each Change Order will detail and specify the requested changes to the applicable task, including details such as responsibility, duty, budget, timeline, Specification or other matter. Whereafter such modified version of the Statement of Work will
be deemed to have replaced the prior version of the Statement of Work. Notwithstanding the foregoing, if a modified version of the Statement of Work is not agreed to by both Parties, the existing Statement of Work shall remain in effect. 

2.3 CLIENT Deliverables. Within the time period specified in a Statement of Work, CLIENT will provide LONZA with (a) the
materials listed in the Statement of Work for which CLIENT is responsible for delivering to LONZA, and any handling instructions, protocols, SOPs and other documentation necessary to maintain the properties of such materials for the performance of
the Statement of Work, and (b) any protocols, SOPs and other information and documentation in possession or control of CLIENT and necessary for the performance of the Statement of Work, and for the preparation of the Project Documentation in
conformance with cGMP, including, without limitation, process information, SOPs, development data and reports, quality control assays, raw material specifications (including vendor, grade and sampling/testing requirements), product and sample
packing and shipping instructions, and product specific cleaning and decontamination information, (collectively, the “CLIENT Development Materials”). If CLIENT does not provide the CLIENT Development Materials [***], then
[***]. 
 2.4 Performance by LONZA. Subject to the provision by CLIENT of the CLIENT Development Materials pursuant to
Section 2.3, LONZA will [***] perform, directly or, subject to the terms of the Statement of Work or approval by CLIENT [***], through a Third Party contractor, the work described in a Statement of Work in a professional and workmanlike manner
in accordance with the terms of this Agreement. LONZA will [***] promptly to notify CLIENT of any [***] delays that arise during the performance of the Statement of Work. 

2.5 Engineering Batches. LONZA shall manufacture Engineering Batches in accordance with the Statement of Work. CLIENT shall have
the right to make whatever further use of the non-cGMP Engineering Batches as it shall determine, provided that CLIENT pays for such Batches, such use is not for human use and does not violate any
applicable laws. [***]. Whether or not a given Engineering Batch will be run using cGMP protocols will be mutually agreed to by the Parties in advance and set forth in each given SOW ([***]). If LONZA determines that an Engineering Batch does meet
cGMP and the Specifications, it will release such Engineering Batch as a cGMP Batch. Regardless of [***], CLIENT shall [***]. 
 2.6
cGMP Batches. LONZA will, in accordance with the terms of this Agreement and Quality Agreement, manufacture at the Facility and release to CLIENT, cGMP Batches that comply with the Process, cGMP and the Specifications, together with a
certificate of analysis; [***]. Prior to commencement of cGMP manufacturing, LONZA shall review the process assumptions. In the event that there is a material difference in the process assumptions as compared with the process results demonstrated
during the manufacture of Engineering Batches, the Parties shall meet to discuss in good faith a revision to the Batch price to reflect such difference. 

2.7 Affiliates. An Affiliate of LONZA may execute a Scope of Work with CLIENT pursuant to this Agreement and submit invoices to
CLIENT under such Scope of Work. In such circumstances, all references in this Agreement to LONZA shall be deemed to be to the applicable Affiliate of LONZA with respect to (i) that particular Scope of Work or (ii) the relevant portions of
a Scope of Work under which the Affiliate will be performing specified Services. The Affiliate shall be entitled to enforce this Agreement with respect to such Scope of Work, or as applicable the relevant portions of such Scope of Work, in its own
name as an intended third party beneficiary and the Affiliate shall be [***] liable to CLIENT for any obligations and liabilities undertaken pursuant to such Scope of Work and subject to the terms of this Agreement. 

  
 4 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 3. TECHNOLOGY TRANSFER 

3.1 Based on the information provided by CLIENT and including process definition or changes developed by LONZA pursuant to any
applicable Statement of Work, LONZA will [***] prepare the Project Documentation for the Process in accordance with the Statement of Work. CLIENT will inform LONZA of any specific requirements CLIENT may have relating to the Project Documentation,
[***]. If [***], LONZA will [***]. The applicable Project Documentation, as set forth in the SOW, shall be completed and delivered by LONZA to CLIENT at completion of a Batch. 

3.2 CLIENT will cooperate with LONZA to assist LONZA to develop the Project Documentation and Process, including, without limitation,
by providing LONZA with additional information and procedures as may be required to create the Project Documentation, Process, and/or any of the following: (i) manufacturing process information, SOPs, development reports, (ii) quality
control assays, (iii) raw material specifications (including vendor, grade and sampling/testing requirements), (iv) Product and sample packing and shipping instructions, (v) Product specific cleaning and decontamination information. 

3.3 LONZA will deliver a draft version of the applicable portions of the Project Documentation to CLIENT for its review and approval in
accordance with the schedule set forth in the Statement of Work. CLIENT will notify LONZA in writing of any objections it has to the draft Master Production Record, and upon such notification, representatives of LONZA and CLIENT will meet promptly
to resolve such objections. Upon CLIENT’s written acceptance of the draft Project Documentation[***], such draft will be deemed approved by CLIENT. 

3.4 The Process, Project Documentation, Specifications, and any improvements or modifications thereto developed during the term of this
Agreement, but excluding any LONZA Operating Documents, LONZA Inventions existing on or prior to the Effective Date, or LONZA Confidential Information included in any of the foregoing, will be deemed CLIENT Confidential Information and subject to
the provisions set forth in Article 10. Subject to Article 11, CLIENT shall be the sole owner of each Process developed by the Parties hereunder and shall be free to use the Process and/or the Project Documentation either alone or with or for the
benefit of any Third Party and to transfer or license the Process to any Third Party manufacturer(s), without any restrictions, payments or other obligations owed to LONZA, to use, manufacture, have manufactured and sell Product; provided,
however, that if the Process and/or the Project Documentation incorporates or contains any LONZA Background Intellectual Property or LONZA Confidential Information as agreed by the Parties under Section 3.1, prior to any disclosure of
such LONZA Background Intellectual Property or LONZA Confidential Information to, or use by, a Third Party manufacturer, CLIENT shall obtain LONZA’s written consent to such disclosure. 

4. MANUFACTURE OF PRODUCT; ORDER PROCESS; DELIVERIES 

4.1 CLIENT Deliverables. Within any time period agreed to in any applicable Statement of Work, CLIENT will provide LONZA with the
materials listed in the Statement of Work required to be supplied by CLIENT for the production of the Product, and any handling instructions, protocols, SOPs and other documentation necessary to maintain the properties of such materials for the
performance of the Statement of Work (collectively, the “CLIENT Production Materials”). 
 4.2
Commencement Date. The Statement of Work will include a Commencement Date agreed upon by the Parties. 
 4.3 Manufacture by
LONZA. LONZA will [***] manufacture, package, ship, handle quality assurance and quality control for the Product all as set forth in the Statement of Work, and to deliver to CLIENT the Product requested by CLIENT in the Statement of Work, all in
accordance with the terms set forth in Section 4.6 below. [***], LONZA shall [***]. 
 4.4 Cancellation of a Statement of
Work. Each Statement of Work shall provide the termination and/or cancellation fees for such Statement of Work (the “Cancellation Fee”); provided, however, that if such Statement of Work does not provide the
termination and/or cancellation fees, the Cancellation Fee shall be [***]. 

  
 5 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 4.5 Payment of Cancellation Fee and Costs. Costs associated with any cancelled
Batch, plus any applicable Cancellation Fee, shall be payable by CLIENT within [***] following the written notice of cancellation associated with the cancelled Batch. 

4.6 Packaging and Shipping. LONZA will package and label the Product for shipment in accordance with the Project Documentation
and LONZA’s standard practices in effect at the time of performance by LONZA. LONZA will ship the Product [***] to a common carrier designated by CLIENT to LONZA in writing not less than [***] prior to the applicable delivery date unless
otherwise agreed to in a Statement of Work. CLIENT will provide to LONZA its account number with the selected carrier and will pay for all shipping costs in connection with each shipment of Product. Each shipment will be accompanied by the
documentation listed in the Statement of Work. Risk and title in and to the Product will pass to CLIENT [***]. LONZA will [***] deliver each shipment of Product to CLIENT on the requested delivery date for such shipment. LONZA will promptly notify
CLIENT if LONZA reasonably believes that it will be unable to meet a delivery date. CLIENT shall be required to take physical possession of a Batch of Product within [***] after acceptance of such Batch in accordance with Section 5.2 (the
“Delivery Period”), unless CLIENT requests in writing, and LONZA consents in writing, to store the material on CLIENT’s behalf and at CLIENT’s expense. 

4.7 Records. LONZA will maintain accurate records for the production of the Product, as required by applicable laws and
regulations. LONZA will retain possession of the Project Documentation, all Batch Records and LONZA Operating Documents, and will make copies thereof available to CLIENT upon CLIENT’s request and at CLIENT’s expense. LONZA Operating
Documents will remain LONZA Confidential Information. CLIENT will have the right to use and reference any of the foregoing in connection with a filing for Regulatory Approval of the Product or as otherwise authorized by the Agreement. 

4.8 CLIENT Access. 

4.8.1 CLIENT’s employees and agents (including its independent contractors) (collectively “CLIENT
Personnel”) may participate in the production of the Product only in such capacities as may be approved in writing in advance by LONZA. CLIENT Personnel working at the Facility are required to comply with LONZA’s Operating
Documents and any other applicable LONZA facility and/or safety policies. For the avoidance of doubt, [***]. 
 4.8.2 CLIENT
Personnel working at the Facility will be and remain employees of CLIENT, and CLIENT will be solely responsible for the payment of compensation for such CLIENT Personnel (including applicable Federal, state and local withholding, FICA and other
payroll taxes, workers’ compensation insurance, health insurance, and other similar statutory and fringe benefits). CLIENT covenants and agrees to maintain workers’ compensation benefits and employers’ liability insurance as required
by applicable Federal and state laws with respect to all CLIENT Personnel working at the Facility. 
 4.8.3 CLIENT will pay for the
actual cost of repairing or replacing to its previous status ([***]) any property of LONZA damaged or destroyed by CLIENT Personnel, provided CLIENT shall not be liable for repair or replacement costs resulting from ordinary wear and tear.

 4.8.4 CLIENT Personnel visiting or having access to the Facility will abide by LONZA standard policies, operating procedures and
the security procedures established by LONZA. CLIENT will be liable for any breaches of security by CLIENT Personnel. In addition, CLIENT will reimburse LONZA for the cost of any lost security cards issued to CLIENT Personnel, at the rate of [***]
per security card. All CLIENT Personnel will agree to abide by LONZA policies and SOPs established by LONZA, and will sign an appropriate confidentiality agreement. 

  
 6 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 4.8.5 CLIENT will indemnify and hold harmless LONZA from and against any and all
losses, damages, liabilities, costs and expenses (including reasonable attorneys’ fees and expenses) arising out of any injuries suffered by CLIENT Personnel while at the Facility or elsewhere, except to the extent caused by the gross
negligence or willful misconduct on the part of any LONZA Party. 
 4.9 Disclaimers. CLIENT acknowledges and agrees that LONZA
Parties will not engage in any Product refinement or development of the Product, other than as expressly set forth in this Agreement and the Statement of Work. CLIENT acknowledges and agrees that LONZA Parties have not participated in the invention
or testing of any Product, and have not evaluated its safety or suitability for use in humans or otherwise. 
 5. PRODUCT
WARRANTIES; ACCEPTANCE AND REJECTION OF PRODUCTS 

5.1 Product Warranties. LONZA warrants that any Product manufactured by LONZA pursuant to this Agreement, at the time of delivery
pursuant to Section 4.6: (a) conforms to the Specifications, [***]; (b) was manufactured in accordance with the Project Documentation; and (c) where applicable, was manufactured in accordance with cGMP[***]. 

5.2 Approval of Completed Product. 

5.2.1 When a cGMP Batch has been completed, LONZA will notify CLIENT and supply CLIENT with the required Project Documentation set
forth in the SOW. Within [***] after CLIENT’s receipt of such documentation regarding such cGMP Batch (the “Acceptance Period”), Client shall determine by review of such documentation whether or not the given cGMP Batch
conforms to the product warranties set forth in Section 5.1 above (“Product Warranties”). If CLIENT asserts that the cGMP Batch does not comply with the Product Warranties set forth in Section 5.1 above, CLIENT will
deliver to LONZA, in accordance with the notice provisions set forth in Section 17.4 hereof, written notice of disapproval (the “Disapproval Notice”) of such cGMP Batch, stating in reasonable detail the basis for such
assertion of non-compliance with the Product Warranties. If a valid Disapproval Notice is received by LONZA during the Acceptance Period, then LONZA and CLIENT will provide one another with all related
paperwork and records ([***]) relating to both the production of the cGMP Batch and the Disapproval Notice. If a valid Disapproval Notice is [***], the cGMP Batch will [***] 

5.2.2 If Product is to be shipped to CLIENT, then upon acceptance, the Product shall be delivered to CLIENT, and CLIENT shall accept
delivery thereof, within [***] after such acceptance. Title and risk of loss to such Product shall pass to CLIENT at the time [***]. If the Product is to be stored by LONZA for CLIENT, LONZA shall do so in accordance with agreed upon terms of a SOW
which covers all relevant details of a Product storage engagement. 
 5.3 Dispute Resolution. LONZA and CLIENT will attempt to
resolve any dispute regarding the conformity of a cGMP Batch with the Product Warranties. If such dispute cannot be settled within [***] of the submission by each Party of such related paperwork and records to the other Party, and if the cGMP Batch
is alleged not to conform with the Product Warranties set forth in Section 5.1(a), then CLIENT will submit a sample of the cGMP Batch of the disputed Product to an independent expert or independent testing laboratory of recognized repute either
of which is selected by CLIENT and approved by LONZA ([***]) for analysis, under quality assurance approved procedures, of the conformity of such cGMP Batch with the Specifications. The costs associated with such analysis by such independent expert
or independent testing laboratory will be paid by the Party whose assessment of the conformity of the cGMP Batch with the Specifications was mistaken. 

5.4 Remedies for Non-Conforming, Damaged, or Destroyed Product. 

5.4.1 In the event that the Parties agree, or an independent testing laboratory determines, pursuant to Section 5.3, that a cGMP
Batch [***] fails to conform to the Product Warranties, or Product and/or Materials are destroyed or damaged by LONZA Personnel, due to the failure of: (a) LONZA personnel properly to [***] (b) LONZA personnel to [***], or (c) [***], then, at
CLIENT’s request, LONZA will, as soon as [***], produce [***] for CLIENT sufficient quantities of Product to replace the non-conforming, damaged or destroyed portion of such cGMP Batch (the
“Production Rerun”), in accordance with the provisions of this Agreement and at no additional cost to CLIENT; provided, however, [***]. If a replacement Product cannot be provided to CLIENT, then LONZA shall
refund the full cost of the original Batch of Product, provided, however, [***]. 

  
 7 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 5.4.2 In the event that the Parties agree, or an independent testing laboratory
determines, pursuant to Section 5.3, that a cGMP Batch materially fails to conform to the Product Warranties, or Product and/or Materials are destroyed or damaged by LONZA Personnel, for any reason other than as set forth in Section 5.4.1,
then LONZA shall [***] and LONZA will, at CLIENT’s request, [***]. Notwithstanding anything to the contrary set forth in Section 5.4, if during the manufacture of Product pursuant to this Agreement, Product or Materials are destroyed or
damaged by LONZA Personnel while LONZA Personnel were [***], then [***]. 
 5.4.3 CLIENT acknowledges and agrees that its [***] with
respect to (i) the failure of Product to conform with any of the Product Warranties and (ii) damaged or destroyed Materials and/or Product, is [***], and in furtherance thereof, Client [***]. 

6. FORECASTS; STRATEGIC MANUFACTURING AGREEMENT 

6.1 No later than the [***] of each calendar quarter, CLIENT shall supply LONZA with a written forecast showing CLIENT’s good faith
estimated quarterly requirements for Batches for the following [***] period (the “Forecast”). No later than [***] following LONZA’s receipt of a Forecast, LONZA shall provide written notice to CLIENT of whether it has
(as of the date of receipt of the Forecast) capacity available to manufacture the number of Batches forecasted therein and shall provide CLIENT with an estimated production schedule showing the estimated Commencement Date and estimated delivery date
of each Batch. The forecast and notice of available capacity given in this Section 6.1 shall not be binding on CLIENT or LONZA. 

6.2 Pursuant to the provisions of Article 7 and Schedule H of the Exclusive License Agreement entered into between CLIENT, Mass. Eye
and Ear Institute, and LONZA dated Sept 9, 2019 (the “Exclusive License Agreement”), CLIENT and LONZA have been negotiating in good faith for the terms and conditions applicable to a potential strategic manufacturing
agreement between CLIENT and LONZA, on the parameters, terms and conditions as outlined for such strategic manufacturing agreement in Article 7 and Schedule H of the Exclusive License Agreement (the “Strategic Agreement”).
LONZA hereby agrees that it shall include all payments made by CLIENT to LONZA for the purchase of manufacturing services under this Agreement, and any and all payments made by CLIENT to LONZA under [***] as counting towards the total spend by
CLIENT under any such Strategic Agreement for the purposes of qualifying for any earned discounts, credits, rebates, refunds or special access benefits based on tiers of total spending thereunder. 

7. STORAGE OF MATERIALS 

7.1 Pre-Production. LONZA will store at the expense of CLIENT any CLIENT Materials,
equipment or other property delivered pursuant to the Statement of Work to the Facility by CLIENT more than [***] prior to the Commencement Date. The storage rates will be set forth in the Statement of Work [***]. No storage fees will be charged
during the period starting [***] prior to the Commencement Date and ending upon completion of the manufacturing of the applicable Product. 

7.2 Post-Production. LONZA will store at the Facility free of charge any in–process materials, CLIENT Materials, equipment
and other CLIENT property (other than Product manufactured hereunder) that remains at the Facility on the date of full Release/lot disposition of the applicable Product (collectively “Remaining CLIENT Property”), for up to
[***]. If CLIENT has not provided any instructions as to the shipment or other disposition of Remaining CLIENT Property prior to the expiration of such [***] period, 

  
 8 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 
LONZA may, in its sole discretion, [***], or continue to store such Remaining CLIENT Property at the Facility or elsewhere. In the event that LONZA continues to store such Remaining CLIENT
Property, CLIENT will pay to LONZA a storage charge at LONZA’s then-standard monthly storage rates for the period beginning on the [***] after the completion of the manufacturing of the applicable Product through the date that the storage
terminates. 
 7.3 Product. Notwithstanding the foregoing, if CLIENT fails to take delivery of a Product within the applicable
Delivery Period as required by Section 4.6, CLIENT will pay to LONZA a storage charge at [***] LONZA’s then-standard monthly storage rate, which shall begin accruing [***]. 

8. REGULATORY MATTERS 

8.1 Permits and Approvals. During the term, LONZA will [***] maintain any licenses, permits and approvals necessary for the
manufacture of the Product in the Facility. LONZA will promptly notify CLIENT if LONZA receives notice that any such license, permit, or approval is or may be revoked or suspended. 

8.2 Inspections/Quality Audit by CLIENT. Except as otherwise set forth in the Quality Agreement, up to [***] per year and upon
not less than [***] prior written notice, LONZA will permit CLIENT to inspect and audit the parts of the Facility where the manufacture of the Product is carried out in order to assess LONZA’s compliance with cGMP, and to discuss any related
issues with LONZA’s management personnel. Such audit shall not last for more than [***]. CLIENT Personnel engaged in such inspection will abide by the terms and conditions set forth in Sections 4.8.4 and 10. 

In addition to the foregoing, CLIENT and/or its representatives shall have the right to perform “For Cause” audits at any time upon
reasonable advance notice and during regular business hours. If a For Cause audit [***], the [***] shall [***]. Notwithstanding the foregoing, a For Cause audit shall also be [***] if it is CLIENT’s sole audit in such calendar year. For the
avoidance of doubt, [***]. 
 8.3 Inspections by Regulatory Agencies. Except as otherwise set forth in the Quality Agreement,
LONZA will allow representatives of any regulatory agency to inspect the relevant parts of the Facility where the manufacture of the Product is carried out and to inspect the Project Documentation and Batch Records to verify compliance with cGMP and
other practices or regulations and will promptly notify CLIENT of the scheduling of any such inspection relating to the manufacture of Product. LONZA will promptly send to CLIENT a copy of any reports, citations, or warning letters received by LONZA
in connection with an inspection of a regulatory agency to the extent such documents relate to or affect the manufacture of the Product. 
 9.
FINANCIAL TERMS 
 9.1 Payments. CLIENT will make payments to LONZA in the amounts and on the
dates set forth in the Statement of Work upon receipt of an invoice from LONZA. In the event that CLIENT has not paid an invoice within [***] of the applicable due date (as established by Section 9.2), CLIENT’s failure shall be considered
a material breach under Section 14.2, subject to the cure provisions set forth therein. Further, in addition to all other remedies available to LONZA, in the event that CLIENT has not paid an invoice within [***] of the applicable due date (as
established by Section 9.2), [***]. 
 9.2 Invoices and Pricing. LONZA will charge for the services in accordance with
the price schedule in each individual Statement of Work. LONZA will invoice CLIENT according to the schedule set forth in a Statement of Work. LONZA will deliver invoices electronically by email, which shall be considered to be an original invoice.
Invoices should be e-mailed to [***], with a copy to [***], and/or to such other e-mail address(es) as CLIENT may stipulate from time to time. LONZA will not deliver a
paper invoice. Payment of invoices is due as provided in the Statement of Work. Unless otherwise provided in the Statement of Work, all pricing excludes taxes and costs relating to shipping, validation and regulatory filings. [***]. Where customer
will be charged separately for raw materials and subcontracted services, Lonza shall provide [***] cost of those raw materials and subcontracted services in the applicable SOW. The actual cost of raw materials and subcontracted services shall be
invoiced to CLIENT [***]. At customer’s reasonable request, Lonza shall provide a detailed breakdown of the actual expenditure to customer. 

  
 9 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 9.3 Credit for CLIENT. CLIENT shall have and be entitled to a credit in the
total amount of [***], so long as CLIENT and LONZA enter into the Strategic Agreement or an amendment to this Agreement which shall include, among other things, the details and parameters for such credit. 

9.4 Taxes. CLIENT agrees that it is responsible for and will pay any sales, use or other taxes (the
“Taxes”) resulting from LONZA’s production of Product under this Agreement (except for income or personal property taxes payable by LONZA). To the extent not paid by CLIENT, CLIENT will indemnify and hold harmless the
LONZA Parties from and against any and all penalties, fees, expenses and costs whatsoever in connection with the failure by CLIENT to pay the Taxes. LONZA will not collect any sales and use taxes from CLIENT in connection with the production of any
Product hereunder if CLIENT provides to LONZA the appropriate valid exemption certificates. 
 9.5 Interest. Any fee, charge
or other payment due to LONZA by CLIENT under this Agreement that is not paid within [***] after it is due will accrue interest [***] from and after such date. 

9.6 Method of Payment. Except as otherwise set forth in Section 9.2, all payments to LONZA hereunder by CLIENT will be in
United States currency and will be by check, wire transfer, money order, or other method of payment approved by LONZA. Bank information for wire transfers is as follows: 

Mailing address for wire transfer payments: 

[***] 
 9.7 [***].
The [***] will be [***], provided, however in no event shall [***]. In addition to the foregoing, the [***]. 
 10.
CONFIDENTIAL INFORMATION 
 10.1 Definition. “Confidential
Information” means all technical, scientific and other know-how and information, trade secrets, knowledge, technology, means, methods, processes, practices, formulas, instructions, skills,
techniques, procedures, specifications, data, results and other material, pre-clinical and clinical trial results, manufacturing procedures, test procedures and purification and isolation techniques, and any
tangible embodiments of any of the foregoing, and any scientific, manufacturing, marketing and business plans, any financial and personnel matters relating to a Party or its present or future products, sales, suppliers, customers, employees,
investors or business, that has been disclosed by or on behalf of such Party or such Party’s Affiliates to the other Party or the other Party’s Affiliates either in connection with the discussions and negotiations pertaining to this
Agreement or in the course of performing this Agreement. Without limiting the foregoing, the terms of this Agreement will be deemed “Confidential Information” and will be subject to the terms and conditions set forth in this Article 10.

 10.2 Exclusions. Notwithstanding the foregoing Section 10.1, any information disclosed by a Party to the other Party
will not be deemed “Confidential Information” to the extent that such information: 
 (a) at the time of disclosure is in
the public domain; 
 (b) becomes part of the public domain, by publication or otherwise, through no fault of the Party receiving
such information; 
 (c) at the time of disclosure is already in possession of the Party who received such information, as
established by contemporaneous written records; 

  
 10 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 (d) is lawfully provided to a Party, without restriction as to confidentiality or
use, by a Third Party lawfully entitled to possession of such Confidential Information; or 
 (e) is independently developed by a
Party without use of or reference to the other Party’s Confidential Information, as established by contemporaneous written records. 

10.3 Disclosure and Use Restriction. Except as expressly provided herein, the Parties agree that for the term of the Agreement
and the [***] period following any termination of the Agreement, each Party and its Affiliates will keep completely confidential and will not publish or otherwise disclose any Confidential Information of the other Party, its Affiliates or
sublicensees, except in accordance with Section 10.4. Neither Party will use Confidential Information of the other Party except as necessary to perform its obligations or to exercise its rights under this Agreement. 

10.4 Permitted Disclosures. Each receiving Party agrees to (i) institute and maintain security procedures to identify and
account for all copies of Confidential Information of the disclosing Party and (ii) limit disclosure of the disclosing Party’s Confidential Information to its U.S. and European Affiliates and each of its and their respective officers,
directors, employees, agents, advisors, consultants and independent contractors having a need to know such Confidential Information for purposes of this Agreement; provided that such U.S. and European Affiliates and each of its and their
respective officers, directors, employees, agents, advisors, consultants and independent contractors are informed of the terms of this Agreement and are subject to obligations of confidentiality,
non-disclosure and non-use similar to those set forth herein. 

10.5 Government-Required Disclosure. If a duly constituted government authority, court or regulatory agency orders that a Party
hereto disclose information subject to an obligation of confidentiality under this Agreement, such Party shall comply with the order, but shall notify the other Party as soon as possible, so as to provide the said Party an opportunity to apply to a
court of record for relief from the order. 
 10.6 Publicity. Neither Party will refer to, display or use the other’s
name, trademarks or trade names confusingly similar thereto, alone or in conjunction with any other words or names, in any manner or connection whatsoever, including any publication, article, or any form of advertising or publicity, except with the
prior written consent of the other Party or as otherwise set forth in Section 10.7. 
 10.7 Publications. For general
business development purposes, LONZA may announce on its website or in press releases the general nature of work performed for CLIENT under any given Statement of Work upon receiving permission from CLIENT, [***]. 

11. INTELLECTUAL PROPERTY 

11.1 Ownership. 

11.1.1 Except as expressly otherwise provided herein, neither Party will, as a result of this Agreement, acquire any right, title, or
interest in any Background Intellectual Property of the other Party. Except as expressly otherwise provided herein, ownership of any Intellectual Property that is developed, conceived, invented, first reduced to practice or made in connection with
the performance under this Agreement shall follow inventorship all as determined under applicable U.S. patent laws. 
 11.1.2 Subject
to Section 11.1.3, CLIENT shall own all right, title, and interest in and to any and all Intellectual Property that LONZA and/or its Affiliates develops, conceives, invents, first reduces to practice or makes, solely or jointly with CLIENT or
others, that is a development, derivative, modification, optimization or improvement to or new use of any CLIENT Materials, CLIENT Confidential Information and/or CLIENT Background Intellectual Property (collectively, “CLIENT New
IP”). For the removal of doubt, CLIENT New IP shall not include LONZA New IP, as defined below. Subject to the terms and conditions set forth herein ([***]), LONZA hereby assigns to CLIENT all of LONZA’s right, title and interest
in and to such CLIENT New IP. LONZA shall promptly disclose to CLIENT in writing all CLIENT New IP. LONZA shall execute, and shall require its personnel as well as its Affiliates, or other contractors or agents and their personnel involved in the
performance of this Agreement to execute, any documents reasonably required to confirm CLIENT’s ownership of CLIENT New IP, and any documents required to apply for, maintain and enforce any patent or other right in the CLIENT New IP. 

 

  
 11 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 11.1.3 Notwithstanding Section 11.1.2, and subject to the license granted in
Section 11.2.2, LONZA shall own all right, title and interest in “LONZA New IP”, which as used in this Agreement means Intellectual Property that LONZA and/or its Affiliates, or other contractors or agents of LONZA
develops, conceives, invents, or first reduces to practice or makes in the course of performance under this Agreement that [***] (ii) is an improvement of, or direct derivative of, any LONZA Materials, LONZA Confidential Information and/or LONZA
Background Intellectual Property. For avoidance of doubt, “LONZA New IP” shall include any material, processes or other items that embody, or that are claimed or covered by, any of the foregoing Intellectual Property. CLIENT hereby assigns
to LONZA all of CLIENT’s right, title and interest in and to such LONZA New IP. CLIENT shall promptly disclose to LONZA in writing all LONZA New IP. CLIENT shall execute, and shall require its personnel as well as its Affiliates, or other
contractors or agents and their personnel involved in the performance of this Agreement to execute, any documents reasonably required to confirm LONZA’s ownership of the LONZA New IP, and any documents required to apply for, maintain and
enforce any patent or other right in the LONZA New IP. 
 11.2 License Grants. 

11.2.1 During the term of this Agreement, CLIENT hereby grants to LONZA a fully paid,
non-exclusive license under any and all CLIENT Intellectual Property that is necessary for LONZA to perform its obligations under this Agreement for the sole and limited purpose of LONZA’s performance of
its obligations under this Agreement, including, without limitation, the development of the Process and the manufacture of Product for CLIENT. 

11.2.2 Subject to the terms and conditions set forth herein ([***]), LONZA hereby grants to CLIENT a
non-exclusive, world-wide, fully paid-up, royalty-free ([***]), irrevocable, transferable license, including the right to grant sublicenses through multiple tiers, under
the LONZA New IP, the LONZA Inventions, and the LONZA Background Intellectual Property to make, have made, use, sell, offer to sell and import the Product manufactured under this Agreement, and to use or to license any Third Party manufacturers to
use the Process generated hereunder in order to make, have made, use, sell, offer to sell and import the Product. 
 11.3 Further
Assurances. Each Party agrees to take all necessary and proper acts, and will cause its employees, Affiliates, contractors, and consultants to take such necessary and proper acts, to effectuate the ownership provisions set forth in this Article
11. 
 11.4 Prosecution of Patents. 

11.4.1 LONZA will have the sole right and discretion to file, prosecute and maintain patent applications and patents claiming LONZA
Inventions or LONZA NEW IP at LONZA’s expense. CLIENT will cooperate with LONZA to file, prosecute and maintain patent applications and patents claiming LONZA Inventions, and will have the right to review and provide comments to LONZA relating
to such patent applications and patents. 
 11.4.2 CLIENT will have the sole right and discretion to file, prosecute and maintain
patent applications and patents claiming CLIENT Inventions or CLIENT New IP at CLIENT’s expense. LONZA will cooperate with CLIENT to file, prosecute and maintain patent applications and patents claiming CLIENT Inventions, and will have the
right to review and provide comments to CLIENT relating to such patent applications and patents. 

  
 12 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 12. REPRESENTATIONS AND WARRANTIES 

12.1 By CLIENT. CLIENT hereby represents and warrants to LONZA that, [***], (i) it has the requisite intellectual property and
legal rights related to the CLIENT Deliverables and the Product to authorize the performance of LONZA’s obligations under this Agreement, and (ii) the performance of the Statement of Work and the production by LONZA of the Product as
contemplated in this Agreement will not give rise to a potential cause of action by a Third Party against LONZA for infringement or another violation of intellectual property rights. Such representation and warranty will not apply to any production
equipment supplied by LONZA or to any LONZA Background Intellectual Property, LONZA Inventions, LONZA New IP or LONZA Confidential Information. 

12.2 By LONZA. LONZA hereby represents and warrants to CLIENT that, [***], (i) it or its Affiliates have the requisite
intellectual property rights in its equipment and Facility to be able to perform its obligations under this Agreement; (ii) that LONZA’s or its Affiliates’ use of the Lonza Background IP or its equipment and Facility as contemplated
in this Agreement will not give rise to a potential cause of action by a Third Party against CLIENT for infringement or another violation of intellectual property rights and (iii) that LONZA will manufacture Product in accordance with cGMP and
all applicable laws[***] (unless the Parties agree otherwise in an SOW). 
 13. DISCLAIMER; LIMITATION OF
LIABILITY 
 13.1 DISCLAIMER. EXCEPT FOR THE EXPRESS WARRANTIES SET FORTH IN THIS AGREEMENT, LONZA MAKES NO
REPRESENTATIONS AND GRANTS NO WARRANTIES, EXPRESS OR IMPLIED, EITHER IN FACT OR BY OPERATION OF LAW, BY STATUTE OR OTHERWISE, WITH RESPECT TO THE PRODUCTS, MATERIALS, AND SERVICES PROVIDED UNDER THIS AGREEMENT, AND LONZA SPECIFICALLY DISCLAIMS ANY
OTHER WARRANTIES, WHETHER WRITTEN OR ORAL, OR EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF QUALITY, MERCHANTABILITY OR FITNESS FOR A PARTICULAR USE OR PURPOSE WITH RESPECT TO SUCH PRODUCTS, MATERIALS, OR SERVICES. 

13.2 Disclaimer of Consequential Damages. IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE OTHER OR ANY OF ITS AFFILIATES FOR ANY
CONSEQUENTIAL, INCIDENTAL, INDIRECT, SPECIAL, PUNITIVE OR EXEMPLARY DAMAGES (INCLUDING, WITHOUT LIMITATION, LOST PROFITS, BUSINESS OR GOODWILL) SUFFERED OR INCURRED BY SUCH OTHER PARTY OR ITS AFFILIATES IN CONNECTION WITH THIS AGREEMENT, EVEN IF
ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. 
 13.3 Limitation of Liability. BOTH PARTIES HEREBY AGREE THAT TO THE FULLEST EXTENT
PERMITTED BY LAW, [***] LIABILITY TO [***], FOR ANY AND ALL INJURIES, CLAIMS, LOSSES, EXPENSES, OR DAMAGES, WHATSOEVER, ARISING OUT OF OR IN ANY WAY RELATED TO THIS AGREEMENT [***], SHALL [***]. TO THE EXTENT THAT [***]. 

14. TERM AND TERMINATION 

14.1 Term. The term of this Agreement will commence on the Effective Date and will continue until the [***] anniversary of the
Effective Date unless terminated prior to that time or extended by the Parties. 
 14.2 Termination for Material Breach.
Either Party may terminate this Agreement, by written notice to the other Party, for any material breach of this Agreement by the other Party, if such breach is not cured within [***] after the breaching Party receives written notice of such breach
from the non-breaching Party; provided, however, that if such breach is not capable of being cured within such [***] period and the breaching Party has commenced and diligently continued actions
to cure such breach within such [***] period, except in the case of a payment default, the cure period shall be extended to [***], so long as the breaching Party is making diligent efforts to do so. Such termination shall be effective upon
expiration of such cure period. 

  
 13 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 14.3 Termination Without Cause. After the first anniversary of the Effective
Date, either Party may terminate this Agreement in its entirety by providing written notice of termination no less than [***] in advance of the date of termination. For the avoidance of doubt, in the event of termination by CLIENT under this
Section 14.3, CLIENT shall, in addition to any fees owed pursuant to Section 4.4, at minimum, remain liable for all fees owed pursuant to any outstanding Statement of Work during such [***] period. 

14.4 Termination by Insolvency. Either Party may terminate this Agreement upon notice to the other Party, upon (a) the
dissolution, termination of existence, liquidation or business failure of the other Party; (b) the appointment of a custodian or receiver for the other Party who has not been terminated or dismissed within [***] of such appointment;
(c) the institution by the other Party of any proceeding under national, federal or state bankruptcy, reorganization, receivership or other similar laws affecting the rights of creditors generally or the making by such Party of a composition or
any assignment for the benefit of creditors under any national, federal or state bankruptcy, reorganization, receivership or other similar law affecting the rights of creditors generally, which proceeding is not dismissed within [***] of filing. All
rights and licenses granted pursuant to this Agreement are, and shall otherwise be deemed to be, for purposes of Section 365(n) of Title 11 of the United States Code, licenses of rights of “intellectual property” as defined therein.

 14.5 Effects of Termination. 

14.5.1 Accrued Rights. Termination of this Agreement for any reason will be without prejudice to any rights that will have
accrued to the benefit of a Party prior to such termination. Such termination will not relieve a Party of obligations that are expressly indicated to survive the termination of this Agreement. Without limitation of the foregoing, in the event of
termination hereunder, LONZA shall be compensated for (i) Services rendered up to the date of termination, including in respect of any Product in-process; (ii) all costs incurred or commitments
through the date of termination, including costs and fees for Materials used or purchased for use in connection with the Services; and (iii) any applicable Cancellation Fees. In the case of termination by LONZA for CLIENT’s material
breach, [***] 
 14.5.2 Disposition of Remaining CLIENT Property and Confidential Information. Upon termination or expiration
of this Agreement, LONZA will store any Remaining CLIENT Property as set forth in Section 7.2 and, at CLIENT’s option, return or destroy any CLIENT Confidential Information in the possession or control of LONZA. Likewise, CLIENT will, at
LONZA’s option, return or destroy any LONZA Confidential Information in the possession or control of CLIENT. Notwithstanding the foregoing provisions: (i) LONZA may retain and preserve, at its sole cost and expense, samples and standards
of each Product following termination or expiration of this Agreement solely for use in determining LONZA’s rights and obligations hereunder; and (ii) each Party may retain a single copy of the other Party’s Confidential Information
for documentation purposes only and which shall remain subject to the obligations of nonuse and confidentiality set forth in this Agreement. 

14.5.3 Survival. [***] of this Agreement, together with any appendices referenced therein, will survive any expiration or termination
of this Agreement. 
 15. INDEMNIFICATION 

15.1 Indemnification of Client. LONZA will indemnify CLIENT, its Affiliates, and their respective directors, officers, employees
and agents, and defend and hold each of them harmless, from and against any and all losses, damages, liabilities, costs and expenses (including reasonable attorneys’ fees and expenses) in connection with any and all liability suits,
investigations, claims or demands (collectively, “Losses”) to the extent such Losses arise out of or result from any claim, lawsuit or other action or threat by a Third Party arising out of: (a) any material breach by
Lonza of any of its obligations under this Agreement or of any representation, warranty or covenant made by Lonza hereunder, or (b) the breach by LONZA of the Product Warranties, or (c) the gross negligence or willful misconduct on the
part of one or more of the LONZA Parties in performing any activity contemplated by this Agreement, except for those Losses for which CLIENT has an obligation to indemnify the LONZA Parties pursuant to Section 15.2, as to which Losses each
Party will indemnify the other to the extent of their respective liability for the Losses. 

  
 14 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 15.2 Indemnification of LONZA. CLIENT will indemnify LONZA and its Affiliates,
and their respective directors, officers, employees and agents (the “LONZA Parties”), and defend and hold each of them harmless, from and against any and all Losses to the extent such Losses arise out of or result from any
claim, lawsuit or other action or threat by a Third Party arising out of: (a) any material breach by CLIENT of this Agreement, (b) the use or sale of Products, except to the extent such Losses arise out of or result from a breach by LONZA
of the Product Warranties, (c) the gross negligence or willful misconduct on the part of CLIENT or its Affiliates in performing any activity contemplated by this Agreement, or (d) the use or practice by LONZA of any process, invention or
other intellectual property supplied by CLIENT to LONZA under this Agreement, except for those Losses for which LONZA has an obligation to indemnify CLIENT pursuant to Section 15.1, as to which Losses each Party will indemnify the other to the
extent of their respective liability for the Losses. 
 15.3 Indemnification Procedure. 

15.3.1 An “Indemnitor” means the indemnifying Party. An “Indemnitee” means the
indemnified Party, its Affiliates, and their respective directors, officers, employees and agents. 
 15.3.2 An Indemnitee which
intends to claim indemnification under Section 15.1 or Section 15.2 hereof shall promptly notify the Indemnitor in writing of any claim, lawsuit or other action in respect of which the Indemnitee, its Affiliates, or any of their respective
directors, officers, employees and agents intend to claim such indemnification. The Indemnitee shall permit, and shall cause its Affiliates and their respective directors, officers, employees and agents to permit the Indemnitor, at its discretion,
to settle any such claim, lawsuit or other action and agrees to the complete control of such defense or settlement by the Indemnitor; provided, however, that in order for the Indemnitor to exercise such rights, such settlement shall
not adversely affect the Indemnitee’s rights under this Agreement or impose any obligations on the Indemnitee in addition to those set forth herein. No such claim, lawsuit or other action shall be settled without the prior written consent of
the Indemnitor and the Indemnitor shall not be responsible for any legal fees or other costs incurred other than as provided herein. The Indemnitee, its Affiliates and their respective directors, officers, employees and agents shall cooperate fully
with the Indemnitor and its legal representatives in the investigation and defense of any claim, lawsuit or other action covered by this indemnification, all at the reasonable expense of the Indemnitor. The Indemnitee shall have the right, but not
the obligation, to be represented by counsel of its own selection and expense. 
 15.4 Insurance. Both Parties will maintain,
at all times during the term of this Agreement and for [***] thereafter, a general commercial liability insurance policy, which shall include products liability coverage [***] (the “Insurance Policy”), with [***], and will
provide a Certificate of Insurance to the other Party that the Insurance Policy has been endorsed to designate the other Party as an additional insured. Both Parties will maintain the Insurance Policy with an insurance company having [***]. The
Parties agree to provide the other with at least [***] written notice prior to termination of such Insurance Policy. 
 16. ADDITIONAL
COVENANTS 
 16.1 Non-Solicitation. During the term of this
Agreement and for [***] thereafter, each of the Parties agrees not to seek to induce or solicit any employee of the other Party or its Affiliates to discontinue his or her employment with the other Party or its Affiliate in order to become an
employee or an independent contractor of the soliciting Party or its Affiliate; provided, however, that neither Party shall be in violation of this Section 16.1 as a result of making a general solicitation for employees or
independent contractors. For the avoidance of doubt, the publication of an advertisement shall not constitute solicitation or inducement. 

  
 15 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 17. MISCELLANEOUS 

17.1 Independent Contractors. Each of the Parties is an independent contractor and nothing herein contained shall be deemed to
constitute the relationship of partners, joint venturers, nor of principal and agent between the Parties. Neither Party shall at any time enter into, incur, or hold itself out to Third Parties as having authority to enter into or incur, on behalf of
the other Party, any commitment, expense, or liability whatsoever. 
 17.2 Force Majeure. Neither Party shall be in breach of
this Agreement if there is any failure of performance under this Agreement (except for payment of any amounts due under this Agreement) occasioned by any reason beyond the control and without the fault or negligence of the Party affected thereby,
including, without limitation, an act of God, fire, flood, act of government or state, war, civil commotion, insurrection, acts of terrorism, embargo, sabotage, a viral, bacterial or mycoplasmal contamination which causes a shutdown of the Facility,
prevention from or hindrance in obtaining energy or other utilities, a shortage of raw materials or other necessary components, labor disputes of whatever nature, or any other reason beyond the control and without the fault or negligence of the
Party affected thereby (a “Force Majeure Event”). Such excuse shall continue as long as the Force Majeure Event continues. Upon cessation of such Force Majeure Event, the affected Party shall promptly resume performance under
this Agreement as soon as it is commercially reasonable for the Party to do so. Each Party agrees to give the other Party prompt written notice of the occurrence of any Force Majeure Event, the nature thereof, and the extent to which the affected
Party will be unable to fully perform its obligations under this Agreement. Each Party further agrees to use commercially reasonable efforts to correct the Force Majeure Event as quickly as practicable (provided that in no event shall a Party
be required to settle any labor dispute) and to give the other Party prompt written notice when it is again fully able to perform such obligations. 

17.3 [***]. If the [***] is [***], then this Agreement will [***]. 

17.4 Notices. Any notice required or permitted to be given under this Agreement by any Party shall be in writing and shall be
(a) delivered personally, (b) sent by registered mail, return receipt requested, postage prepaid, (c) sent by a nationally-recognized courier service guaranteeing next-day or second day
delivery, charges prepaid, or (d) delivered by facsimile (with documented evidence of transmission), to the addresses or facsimile numbers of the other Party set forth below, or at such other addresses as may from time to time be furnished by
similar notice by any Party. The effective date of any notice under this Agreement shall be the date of receipt by the receiving Party. 

If to LONZA: 
 Lonza
Houston, Inc. 
 Attn: Business Head 

14905 Kirby Dr. 
 Houston, TX
77047 
 With a copy to: 

Assistant General Counsel 
 Lonza
America, Inc. 
 90 Boroline Road 

Allendale, NJ 07401 
 Fax: [***]

  
 16 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 If to Client: 

Attn: [***], Chief Technology Officer 

Affinia Therapeutics, Inc. 
 43
Foundry Ave, 
 Suite 120 

Waltham, MA 02453 
 Email: [***]

 With a copy to: 
 Attn:
[***], Chief Legal Officer 
 Affinia Therapeutics, Inc. 

43 Foundry Ave, 
 Suite 120 

Waltham, MA 02453 
 Email: [***]

 Either Party may change its address for notice by giving notice thereof in the manner set forth in this Section 17.4. 

17.5 Entire Agreement; Amendments. This Agreement, including the Appendices attached hereto and referenced herein, constitutes
the full understanding of the Parties and a complete and exclusive statement of the terms of their agreement with respect to the specific subject matter hereof and supersedes all prior agreements and understandings, oral and written, among the
Parties with respect to the subject matter hereof. No terms, conditions, understandings or agreements purporting to amend, modify or vary the terms of this Agreement (including any Appendix hereto) shall be binding unless hereafter made in a written
instrument referencing this Agreement and signed by each of the Parties. 
 17.6 Governing Law. The construction, validity and
performance of the Agreement shall be governed by and construed in accordance with the internal laws of the [***], without giving effect to its conflicts of laws provisions. 

17.7 Counterparts. This Agreement and any amendment hereto may be executed in any number of counterparts, each of which shall
for all purposes be deemed an original and all of which shall constitute the same instrument. This Agreement shall be effective upon full execution by facsimile or original, and a facsimile signature shall be deemed to be and shall be as effective
as an original signature. 
 17.8 Severability. If any part of this Agreement shall be found to be invalid or unenforceable
under applicable law in any jurisdiction, such part shall be ineffective only to the extent of such invalidity or unenforceability in such jurisdiction, without in any way affecting the remaining parts of this Agreement in that jurisdiction or the
validity or enforceability of the Agreement as a whole in any other jurisdiction. In addition, the part that is ineffective shall be reformed in a mutually agreeable manner so as to as nearly approximate the intent of the Parties as possible. 

17.9 Titles and Subtitles. All headings, titles and subtitles used in this Agreement (including any Appendix hereto) are for
convenience only and are not to be considered in construing or interpreting any term or provision of this Agreement (or any Appendix hereto). 

17.10 Exhibits. All “RECITALS”, “DEFINITIONS”, exhibits and appendices referred to herein form an integral
part of this Agreement and are incorporated into this Agreement by such reference. 
 17.11 Pronouns. Where the context
requires, (i) all pronouns used herein will be deemed to refer to the masculine, feminine or neuter gender as the context requires, and (ii) the singular context will include the plural and vice versa. 

  
 17 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 17.12 Assignment. This Agreement shall be binding upon the successors and
assigns of the Parties and the name of a Party appearing herein shall be deemed to include the names of its successors and assigns. Neither Party may assign its interest under this Agreement without the prior written consent of the other Party, such
consent not to be unreasonably withheld; provided, however, that either Party shall be entitled without the prior written consent of the other Party to assign this Agreement to an Affiliate or to any company to which the assigning
Party may transfer all or substantially all of its assets or capital stock relating to the activities contemplated under this Agreement, whether through purchase, sale, merger, consolidation, change of control or otherwise; provided,
further, however, [***]. Any permitted assignment of this Agreement by either Party will be conditioned upon that Party’s permitted assignee agreeing in writing to comply with all the terms and conditions contained in this
Agreement. Any purported assignment without a required consent shall be void. No assignment shall relieve any Party of responsibility for the performance of any obligation that accrued prior to the effective date of such assignment. 

17.13 Waiver. The failure of any Party at any time or times to require performance of any provision of this Agreement (including
any Appendix hereto) will in no manner affect its rights at a later time to enforce the same. No waiver by any Party of any term, provision or condition contained in this Agreement (including any Appendix hereto), whether by conduct or otherwise, in
any one or more instances, shall be deemed to be or construed as a further or continuing waiver of any such term, provision or condition or of any other term, provision or condition of this Agreement (including any Appendix hereto). 

17.14 Dispute Resolution. If the Parties are unable to resolve a dispute, despite its good faith efforts, either Party may refer
the dispute to the President of each Party’s respective business unit (or other designee). In the event that no agreement is reached by the Presidents (or other designees) with respect to such dispute within [***] after its referral to them,
either Party may pursue any and all remedies available at law or in equity. 
 17.15 No Presumption Against Drafter. For
purposes of this Agreement, CLIENT hereby waives any rule of construction that requires that ambiguities in this Agreement (including any Appendix hereto) be construed against the drafter. 

[***] 

  
 18 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 IN WITNESS WHEREOF, the
parties have executed this Agreement as of the date last signed by the parties hereto. 
  

									
	4/29/2021	 		 	AFFINIA THERAPEUTICS, INC.
					
		 	 	 		 	By:	 	/s/ [***]
		 	Date	 		 		 	 Name: [***]
 Title: Chief Legal
Officer

  

									
	4/29/2021	 		 	 LONZA HOUSTON, INC. 

					
		 	 	 		 	By:	 	/s/ [***]
		 	Date	 		 		 	 Name: [***]
 Title: VP, Sales and Program
Management

 SIGNATURE PAGE TO MANUFACTURING
SERVICES AGREEMENT 

  

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 

 
  
 APPENDIX A 

STATEMENT OF WORK 
 TO
BE ATTACHED 

  

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 AMENDMENT No. 1 TO MANUFACTURING SERVICES AGREEMENT 

This First Amendment (the “Amendment No. 1”) effective as of August 9, 2021 (the
“Amendment No. 1 Effective Date”) to that certain Manufacturing Services Agreement (the “Agreement”), effective as of April 30, 2021 between
LONZA HOUSTON, INC. located at 14905 Kirby Drive, Pearland, TX 77047 (“LONZA”), and AFFINIA THERAPEUTICS, INC. a Delaware
corporation with a place of business at 43 Foundry Ave, Suite 120, Waltham MA 02453 (“AFFINIA”), (each of LONZA and AFFINIA, a “Party” and, collectively, the “Parties”). 

WHEREAS, LONZA and AFFINIA are parties to the Agreement; and WHEREAS, AFFINIA desires to secure manufacturing capacity at the Facility;
and 
 WHEREAS, the Parties are desirous of amending the Agreement by agreeing to this Amendment No. 1 and the terms and
conditions herein, to supplement the provisions of the Agreement. 
 NOW THEREFORE, in consideration of the above premises and the
mutual covenants herein set forth, the Parties hereto agree as follows: 
  

	 	1.	 Section 4.10 shall be added to the Agreement to read as follows: 

4.10 Pass-through Costs Handling Fees. LONZA will charge AFFINIA a [***] Handling Fee on all pass through costs of
materials and external services. All pass through costs will be capped at [***] for all AFFINIA programs during the Term of the Agreement. 
  

	 	2.	 Section 6.1 of the Agreement is hereby deleted and replaced in the entirety with the following:

 6.1 Forecast and Capacity Reservation for AFFINIA. No later than the [***] of each calendar
quarter, AFFINIA shall supply LONZA with a written forecast showing AFFINIA’s good faith estimated quarterly requirements for Batches for the following [***] period (the “Forecast”). The Forecast shall be subject to the
provisions of Appendix B, Capacity Reservation. Lonza shall reserve and provide dedicated manufacturing capacity for AFFINIA during the Term in accordance with the provisions, terms and conditions of Appendix B, Capacity Reservation. 

 

	 	3.	 Section 6.2 of the Agreement is hereby deleted. 

 

	 	4.	 Section 9.3 of the Agreement is hereby amended to read as follows: 

9.3 Credit for AFFINIA. In each calendar year of the Term, [***] (each such calendar year shall be referred to as a
“Contract Year”), AFFINIA can earn a credit of [***] of the total amount invoiced by LONZA in that year, excluding the price of pass through costs such as raw materials and external testing fees. The total amount of credit
shall not exceed [***] over the duration of the Initial Term. The credit shall be applied in full to invoices of the following Contract Year, with the exception of the last Contract Year of the Term, in which case the final invoices will be reduced
by the credit amount as applicable. The total spend calculation for 2021 shall also include all invoices (excluding the price of pass through costs such as raw materials and external testing fees) paid by AFFINIA in the calendar year 2020. 

  

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

	 	5.	 Section 14.1 of the Agreement is hereby deleted and replaced with the following: 

14.1 Term. The term of this Agreement will commence on the Effective Date and will continue until December 31, 2026
(the “Initial Term”) unless terminated prior to that time or extended by the Parties. Extensions of [***] shall be by mutual written agreement (each, an “Extension Term”) and the
“Term” of the Agreement shall be defined collectively as the Initial Term plus any mutually agreed Extension Terms. 
  

	 	6.	 APPENDIX B is hereby incorporated by reference and added to the Agreement as follows: 

APPENDIX B 
 CAPACITY
RESERVATION 
  

	 	1.	 Capacity reservation. During the Term, LONZA will reserve for AFFINIA and provide to AFFINIA two
(2) dedicated [***] manufacturing slots per Contract Year based on the quarterly Forecast provided by AFFINIA per Section 6.1 of the Agreement. AFFINIA will work in good faith with LONZA to determine the commencement date and duration
needed each year for each of such two manufacturing slots. For clarity, a reserved manufacturing slot can be used for either an Engineering lot or for a GMP lot, at AFFINIA’s sole discretion. 

Each of the two manufacturing slots shall be reserved for AFFINIA [***]. At AFFINIA’s request, a manufacturing slot may be scheduled
[***], subject to [***]. 
 The details of the Product to be manufactured and Price for the Batch(es) shall be captured in an SOW to be
agreed between the Parties. 
  

	 	2.	 Reservation Fee. On [***] of each Contract Year during the Term commencing in 2022, LONZA will invoice a
non-refundable reservation fee of [***] per Contract Year for the two manufacturing slots being reserved for AFFINIA for the following Contract Year. Reservation Fees will not be invoiced or owed in the final
Contract Year of the Term. The Reservation Fees [***]. The [***] manufacturing slots are [***]. 

 The Reservation Fee
payments shall be considered pre-payment for [***] to be reserved for AFFINIA during the Initial Term, and shall be applied in full to the Batch price. Subject to the limitations set forth in Paragraph 4 of
this Appendix B, the applicability of a Reservation Fee against the Batch price shall [***]. However, in the event that [***]. 
  

	 	3.	 Cancellation Fees. Cancellation of any Batch by AFFINIA, whether covered by a Reservation Fee or not,
shall be subject to the following Cancellation Fees: 

 [***] 

 

	 	4.	 Rescheduling of Reserved Capacity by AFFINIA. In the event the [***] reserved manufacturing slot in a
given Contract Year is not required by AFFINIA (at AFFINIA’s sole discretion) and AFFINIA provides notice of such at least [***] prior to the Batch commencement date, subject to capacity availability, the manufacturing slot requirement will be
added to a later Contract Year of the Term. In such case, the Reservation Fee for the canceled manufacturing slot shall [***]. If LONZA cannot reasonably accommodate the additional slot for a later Contract Year, despite making good faith reasonable
commercial efforts to do so, [***]. In such event, Lonza will accommodate the rescheduling request by providing a manufacturing slot of [***], and if Lonza is unable to do so despite making reasonable commercial efforts, the Reservation Fee paid by
AFFINIA for that slot shall be credited in full by LONZA and AFFINIA can use such credit against other Batch invoices or any other invoices owed under the Agreement. 

  
 22 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

	 	5.	 Termination. In the event of any early Termination of the Agreement by either Party per Section 14
of the Agreement, no additional Reservation Fees shall be owed by or charged to AFFINIA during the termination notice period beyond those that were already due and payable by AFFINIA prior to the date that written notice of termination was provided
by either Party to the other Party in accordance with the provisions of Section 14 of the Agreement. Any Reservation Fee(s) paid by AFFINIA prior to the date of the Termination notice shall be applied to the applicable Batch(es) scheduled for
manufacturing in the Termination notice period. Any remaining Reservation Fees for Batches that were scheduled outside of the Termination notice period and are therefore canceled, shall be [***] 

 

	 	7.	 All capitalized terms not defined herein shall have the respective meanings ascribed to them in the Agreement.

  

	 	8.	 Remainder of Agreement. Except as expressly modified by this Amendment No. 1, all other terms, conditions
and provisions of the Agreement shall remain in full force and effect in accordance with their terms. 

  

	 	9.	 Entire Agreement. This Amendment No. 1 and the Agreement supersede all other prior agreements,
understandings, representations and warranties, oral or written between the Parties hereto in respect of the subject matter hereof. This Amendment No. 1 may be executed in any number of counterparts, each of which shall be deemed to be an
original and all of which together shall constitute one and the same document. Each Party acknowledges that an original signature or a copy thereof transmitted by facsimile or by pdf or other electronic means shall constitute an original signature
for purposes of this Amendment No. 1. 

 [***] 

  
 23 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 IN WITNESS WHEREOF the Parties have caused this Amendment No. 1 to be executed by their
duly authorized respective representatives effective as of the Amendment No. 1 Effective Date. 
  

			
	AFFINIA THERAPEUTICS, INC.
		
	 By:
	 	 /s/ [***]

		 	 Name: [***]

		 	 Title: Chief Legal Officer

		 	 Date: 8/23/2021

  

			
	LONZA HOUSTON, INC.
		
	 By:
	 	 /s/ [***]

		 	 Name: [***]

		 	 Title: Director, Customer Proposals

		 	 Date:
24-Aug-21

  

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00338-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00338-of-00352.parquet"}]]